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ANALYSIS OF E2F1 TARGET GENES INVOLVED IN CELL CYCLE AND 
APOPTOSIS 
 
Scott N. Freeman 
ABSTRACT 
 
 One of the main results of Rb-E2F pathway disruption is deregulation of the E2F 
family of transcription factors, which can lead to inappropriate proliferation, oncogenic 
transformation, or the induction of apoptosis. Given the potential negative biological 
effects associated with deregulated E2F activity, it is of great importance to study E2F 
targets that mediate these effects. In Part I of this manuscript, we identify the RhoBTB2 
putative tumor suppressor gene as a direct physiological target of the E2F1 transcription 
factor. We find that RhoBTB2 is highly upregulated during mitosis due in part to E2F1, 
and that overexpression of RhoBTB2 increases the S-phase fraction and slows the rate of 
proliferation. We also find RhoBTB2 similarly upregulated during drug-induced 
apoptosis due primarily to E2F1 and that knockdown of RhoBTB2 expression via siRNA 
slows drug-induced apoptosis. Taken together, we describe RhoBTB2 as a novel direct 
target of E2F1 with roles in cell cycle and apoptosis. 
In Part II, we independently identify from cancer cell lines two novel variants 
from the promoter of E2F1 target MCL-1—MCL-1 +6 and +18—as initially published 
by Moshynska et al (1). In contrast to Moshynska et al., we find the variant promoters 
identically present in both cancerous and adjacent noncancerous clinical lung samples, 
x 
suggesting that the variants are germ-line encoded. We also find the variant promoters 
prevalent in genomic DNA derived from healthy control samples and present at 
frequencies similar to that observed in cancerous cell lines. In further contrast, we find 
the activity of the MCL-1 +6 and +18 promoters approximately 50% less than the 
common MCL-1 +0 promoter—both during normal cellular homeostasis and under 
conditions that actively induce Mcl-1 transcription. Given our results and those of others, 
we conclude that the MCL-1 +6 and +18 promoters are likely benign polymorphisms and 
do no represent a reliable prognostic marker for CLL as reported by Moshynska et al.
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PART I 
 
RHOBTB2 (DBC2) IS A MITOTIC E2F1 TARGET WITH A NOVEL ROLE IN 
APOPTOSIS 
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Abstract 
 
We have identified the RhoBTB2 putative tumor suppressor gene as a direct 
target of the E2F1 transcription factor. Overexpression of E2F1 leads to upregulation of 
RhoBTB2 at the levels of mRNA and protein. This also occurs during the induction of an 
estrogen receptor-fused E2F1 construct by 4-hydroxytamoxifen in the presence of 
cyclohexamide, thus indicating that RhoBTB2 is a direct target. RNAi-mediated 
knockdown of E2F1 expression decreases RhoBTB2 protein expression, demonstrating 
that RhoBTB2 is a physiological target of E2F1. Since E2F1 primarily serves to 
transcribe genes involved in cell cycle progression and apoptosis, we explored whether 
RhoBTB2 played roles in either of these processes. We find RhoBTB2 expression highly 
upregulated during mitosis, which is partially dependent on the presence of E2F1. 
Furthermore, overexpression of RhoBTB2 leads to an increase in the S-phase fraction of 
asynchronously growing cells and also slows the rate of proliferation. We similarly find 
RhoBTB2 upregulated during drug-induced apoptosis, and that this is primarily 
dependent on E2F1. Finally, we demonstrate that knockdown of RhoBTB2 levels via 
siRNA slows the rate of drug-induced apoptosis. Taken together, we describe RhoBTB2 
as a novel direct target of E2F1 with roles in cell cycle and apoptosis. 
3 
 
 
 
 
 
Introduction 
 
The Rb-E2F pathway 
 
The Retinoblastoma (Rb)-Early 2 Factor (E2F) pathway is a critical regulator of 
molecular mechanisms governing various aspects of cell proliferation, differentiation, 
and survival (for review, see refs. (2-6)). It regulates these biological effects by 
integrating both positive and negative signals to ultimately control the transcriptional 
repression or activation of genes involved in the aforementioned processes. Given the 
importance of tight regulation of proliferation, differentiation, and survival in the 
avoidance of human malignancy, it is not surprising to find that this pathway is aberrantly 
regulated by various means in almost every instance of human malignancy (7). One of 
the results of deregulation of the Rb-E2F pathway is unrestrained transcriptional 
activation by certain members of the E2F family of proteins, which can contribute to 
oncogenic transformation (4). Indeed, many identified E2F target genes play direct roles 
in the biological effects associated with deregulation of the Rb-E2F pathway (8,9). Yet 
while many crucial E2F targets associated with the biological phenotype of deregulated 
Rb-E2F have been identified, many more remain to be characterized. Given the 
prevalence of Rb-E2F pathway deregulation in human malignancy and the role of E2F 
4 
targets in mediating the biological effects, characterizing E2F target genes involved in 
this process is of great importance. 
At the center of a cell’s decision to divide is the Rb-E2F pathway, and as such one 
of its major roles is to regulate the G1/S-phase transition. While the function of the 
pathway encompasses more than regulation of this transition, its model of activity is best 
explained under that context. In this model, the Rb-E2F pathway responds to both pro- 
and anti-proliferative signals to either activate or repress the transcription of genes 
involved in further cell cycle progression and DNA synthesis. Many reviews have 
thoroughly documented this functional paradigm (6,10,11), and the reader is encouraged 
to reference these for greater detail. As such, only a brief description of the current 
paradigm is provided.  
As illustrated in figure 1, in cells that are in a resting or quiescent state, the pRb 
protein resides hypophosphorylated, which allows it to restrain the transcriptional activity 
of E2F proteins. Mitogenic signaling in early G1 or G0 serves to upregulate the expression 
of D-type cyclins—the regulatory subunit of the cyclin D/cyclin-dependent kinase (cdk) 
4/6 complex. Cyclin D binds to cdk4/6 to create the active kinase complex, which along 
with the reported activity of Raf-1, places the initial phosphorylation events on pRb 
family proteins (12-14). Phosphorylation of pRb family proteins decreases their ability to 
inhibit E2F family members, thus freeing some transcriptionally active DRTF1-
polypeptide (DP)/E2F complex. This free complex sets in motion a feed-forward 
mechanism that results in increased expression of E2F target genes such as E2F1, E2F2, 
and E2F3a, as well as cyclin E, the regulatory subunit of the cyclin E/cdk2 complex  
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Figure 1. The Rb-E2F pathway. Mitogenic signaling in G0/G1 upregulates cyclin D1 
and Raf-1, which contributes to phosphorylation of pRb family proteins—thus relieving 
some inhibition of E2F/DP complex. Further E2F-mediated upregulation of cyclin E at 
the G1/S-phase transition leads to additional phosphorylation of pRb by cyclin E/cdk2 
complex, leading to full inactivating of pRb. This initiates S-phase entry and allows 
E2F/DP complex to activate the transcription of genes involved in DNA replication, 
further cell cycle progression, and genes that subsequently deactivate E2F and DP. 
5 
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(15-18). Cyclin E binds to cdk2, the catalytic subunit, to create the active kinase complex, 
and the main target of the cyclin E/cdk2 complex is again the pRb protein (19). Cyclin 
E/cdk2 complex fully phosphorylates pRb, thus allowing for the full induction of E2F 
target genes. 
Among the many genes induced by E2F family proteins at this stage of the cell 
cycle include those involved in further cell cycle progression, DNA replication, and 
nucleotide biosynthesis. Subsequent sections discuss the full range of E2F target genes in 
greater detail; however, it should be noted that two important targets of E2F at this stage 
of the cell cycle are cyclin A and S-phase kinase-associated protein 2 (Skp2), which are 
responsible for down-regulating E2F activity through two separate mechanisms (20,21). 
Cyclin A is another regulatory subunit for cdk2 which, along with promoting further cell 
cycle progression, phosphorylates E2F and DP family proteins when in complex with 
cdk2—resulting in a decreased ability to bind DNA (19,22). Skp2 activity also decreases 
E2F activity through ubquitination, thus targeting it for proteasomal degradation (23). 
 
Mechanisms of Rb-E2F pathway disruption in human malignancy 
 
 One of the defining features of malignancy is uncontrolled cellular proliferation, 
and given the pivotal role that the Rb-E2F pathway plays in regulating this process, it is 
not surprising to find that disruption of the Rb-E2F pathway is a unifying factor in 
virtually every instance of human malignancy (7). An examination of figure 1 reveals 
multiple potential points for deregulation, and indeed, most have been described in the 
literature. Figure 2 provides examples of various methods employed by malignant cells to
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Figure 2. Examples of Rb-E2F pathway disruptions in human malignancy. The Rb-
E2F pathway is subject to various regulatory mechanisms that prevent inappropriate 
proliferation, however malignant cells override these controls through various oncogenic 
mutations. Some examples described in human malignancy include activating mutations 
in receptor tyrosine kinases, activating mutations in signaling molecules such as Src, 
amplification or upregulation of cyclin D or cdk4, deletion of CKI p16INK4a, deletion or 
mutation of Rb, and amplification of E2F. 
8 
circumvent control mechanisms preventing inappropriate entry into the cell cycle, yet this 
is by no means a comprehensive list of all reported mechanism utilized to deregulate Rb-
E2F pathway in human malignancy. 
 The most obvious and most prominent point of deregulation lies with the RB1 
gene itself. Indeed, the RB1 gene was first described in its namesake retinoblastoma as 
being the inherited genetic component behind this childhood familial malignancy of the 
eye (24,25). Interestingly, RB1 has the notorious distinction of being the first identified 
tumor suppressor gene. While identified as an inherited genetic component contributing 
to malignancy, it has become clear that somatically arising disruptions of the RB1 gene 
by means of deletion or mutation are more common in malignancy than inherited germ-
line mutations (7). 
 In addition to the RB1 gene itself, genetic alterations in regulators of pRb 
phosphorylation status are also very prevalent. The p16INK4A protein is a member of a 
family of cyclin-dependent kinase inhibitors (CKIs) that directly oppose the action of 
cyclin/cdk complexes. p16INK4A specifically inhibits the activity of cyclin D/cdk4/6 
complexes, thus inhibiting pRb phosphorylation (26). Not withstanding, disruption of 
p16INK4A activity by means of deletion, mutation, or promoter methylation is also well 
documented. Similarly, the p16INK4A target cyclin D/cdk4/6 is frequently altered in cancer 
by means of amplification or translocation of either cyclin D or cdk4/6. The end result of 
both of these aberrances is unwarranted inactivation of pRb (7). 
 It was long thought that genetic aberrances in E2F genes themselves were not a 
common occurrence in malignancy, yet recent reports have identified a handful of genetic 
alterations in E2F. Amplification of E2F3 is present in some retinoblastomas and urinary 
9 
bladder carcinomas (27-31), and amplification of E2F1 has been reported in melanoma, 
colorectal, esophageal, and ovarian cancers (32-37). While upregulation of the activating 
E2Fs is a common occurrence in malignancy, it is not understood why genetic aberrances 
in the E2F gene itself are not more prevalent. 
 
Deregulated E2F activity 
 
 One of the main results of Rb-E2F pathway disruption is deregulation of the E2F 
family of transcription factors. This can manifest itself through both the loss of ability to 
repress E2F target genes—mediated primarily by the repressive E2Fs in complex with 
pRb, and the loss of ability to restrain gene transactivation, which is primarily a function 
of the activating E2Fs. Since the subsequent experiments concentrate on the 
consequences of deregulated E2F-mediated gene transactivation in malignancy, 
mechanisms relating to the loss of ability to repress E2F target genes are not discussed. 
Likewise, studies utilizing loss-of-function techniques to determine physiological 
functions of E2F are also not discussed. Instead, the subsequent sections describe the 
various members and subgroups within the E2F family and the biological effects 
associated with deregulated E2F transactivation—primarily being the promotion of 
proliferation and oncogenesis and the induction of apoptosis. It should be noted that 
under some contexts, deregulated E2F can paradoxically promote survival, induce growth 
arrest, or contribute to tumor suppression (38-45). While the mechanisms and contexts of 
these biological effects are not as well-defined, in many instances they are dependent on 
the presence of one or more tumor suppressors such as p19ARF, p53, p21, p16INK4A, or Rb, 
10 
which is often not the case in cancer (42-45). However, studies examining this seemingly 
contradictory role of deregulated E2F are relevant to the present study and are also 
addressed. 
 
The E2F family of transcription factors 
 
Nine E2F family members have been identified to date (E2F1-8, with E2F3 
having two variants: E2F3a and E2F3b) and have traditionally been divided into three 
subgroups based on both structure and function (46-62). However, emerging data 
illustrating the highly complex nature of function within the E2F family has rendered this 
view overly simplistic (3). It is clear though that in general terms, certain subgroups of 
E2Fs are more associated with either target gene transactivation or target gene repression, 
and in the interest of presenting an overview of members within the E2F family, the 
traditional model will be utilized. 
 E2F1, E2F2, and E2F3a constitute the first subgroup of E2Fs and are commonly 
referred to as the ‘activating’ E2Fs by virtue of their ability to potently activate the 
transcription of genes from model promoters. Structurally, these E2Fs contain an N-
terminal nuclear localization sequence (NLS) and cyclin A/cdk2-binding domain 
followed by a DNA-binding domain, a DP dimerization domain and a C-terminal 
transactivation/pRb-binding domain (Fig. 3, top). These E2Fs associate exclusively with 
pRb and not p107 or p130. In normal cells, the expression of these E2Fs is tightly 
coupled to cell cycle, with expression increasing transcriptionally upon mitogenic 
stimulation in G1 (15,16,63), and decreasing in part due to post-translational modification
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Figure 3. The E2F family of transcription factors. The E2F family of transcription 
factors is commonly divided into the activating, repressive and atypical subgroups. The 
activating E2Fs consist of E2F1, E2F2, and E2F3a and contain a NLS and cyclin A/cdk2 
binding domain, DNA-binding domain, DP dimerization domain, and a pRb family 
member-binding domain. The repressive E2Fs are E2F3b, E2F4, and E2F5 and contain a 
DNA-binding domain, DP-dimerization domain, and pRb family member-binding 
domain. While E2F3b contains a NLS, E2F4 and E2F5 harbor a NES. The atypical E2Fs 
are E2F6, E2F7, and E2F8. E2F6 contains a DNA-binding domain and RYBP-binding 
domain, and E2F7 and E2F8 contain a tandem of two DNA-binding domains. 
11 
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imposed by the activity of Skp2 in late S-phase, which targets E2F1 for proteasomal 
degradation (23). These E2Fs have been implicated in promoting the transcription of a 
multitude of genes with various cellular functions, which is discussed in greater detail in 
further sections. 
 The second subgroup of E2Fs is made up of E2F3b, E2F4, and E2F5 and is 
commonly referred to as the ‘repressive’ E2Fs due to their poor ability to activate 
transcription, as well as their potent ability to repress transcription when in complex with 
pRb family members. While E2F3b contains an N-terminal NLS and cyclin A/cdk2-
binding domain, this sequence is absent from E2F4 and E2F5, which instead have a 
nuclear exclusion sequence (NES) following the DNA-binding domain (Fig. 3, middle). 
These E2Fs also contain a DP dimerization domain and a C-terminal pRb family 
member-binding domain. While E2F3b associates exclusively to pRb, E2F4 can associate 
with pRb, p107, or p130, and E2F5 only associates with p130. In contrast to the 
activating E2Fs, expression of the repressive E2Fs is relatively static throughout the cell 
cycle. Given the constant nature of expression of E2F4 and E2F5, it stands to reason that 
other mechanisms are in place to regulate their activity. Indeed, these E2Fs are regulated 
by localization—with inactive E2F4 and E2F5 being cytoplasmic and association with 
pRb or DP family members being required for nuclear import (11). It appears that the 
primary role of E2F3b, E2F4, and E2F5 is to repress the transcription of E2F target genes 
through the recruitment of repressive complexes containing pRb family members. 
 The final subgroup of E2Fs will be referred to as the ‘atypical’ E2Fs due to their 
divergence from E2F1-5. These E2Fs have been identified more recently, and therefore 
less is known about their cellular functions. E2F6 was the first identified atypical E2F 
13 
and contains only one E2F family conserved sequence: the DNA-binding domain (Fig. 3, 
bottom). Given the absence of a pRb-binding domain, E2F6 does not bind to pRb family 
members, but instead recruits components of the mammalian polycomb group complex 
through a RING1 and YY1-binding protein (RYBP) domain to repress the transcription 
of E2F target genes (64). E2F7 and E2F8 represent an entirely new class of E2Fs whose 
homology to other E2F family members is limited to a tandem of two DNA-binding 
domains (Fig. 3, bottom). Given the lack of pRb-binding or dimerization domains, these 
E2Fs are thought to bind DNA independent of DP or pRb. The limited amount of studies 
examining the functions of E2F7 and E2F8 suggest that these proteins act as repressors of 
transcription through as yet uncharacterized mechanisms (58,59,62,65). 
 
Promotion of proliferation and oncogenesis 
 
One of the most pronounced biological effects of unrestrained transactivation by 
the activating E2Fs is the promotion of cell cycle progression, which is typically 
manifested as inappropriate S-phase entry. In cell culture-based assays utilizing rodent 
fibroblasts, overexpression of E2F1, E2F2 or E2F3a is capable of inducing S-phase entry 
from quiescence (66-69), and in the case of E2F1, can override anti-proliferation signals 
imposed by the expression of CKIs p16, p21, p27 or treatment with TGF-β (70-72). This 
potent ability to promote cell cycle progression can also manifest in the transformation of 
primary cells, where overexpression of E2F1, E2F2, or E2F3 can induce transformation 
either alone or in combination with oncogenic ras (73-76). 
14 
The pro-proliferative and oncogenic effects of E2F overexpression observed in 
cell culture-based assays are also evident in vivo by means of mice transgenic for E2F, 
where transgenic expression of E2F can promote inappropriate entry into the cell cycle, 
hyperplasia, and even tumor formation. Consistent with the in vitro models, transgenic 
expression of E2F1, E2F2 or E2F3a targeted to the lens fiber is capable of inducing 
reentry into the cell cycle in postmitotic cells (77,78). Transgenic E2F4 can also induce 
cell cycle reentry in this model, albeit to a lesser extent (77). When expressed under 
control of the megakaryocyte-specific platelet factor 4 promoter, E2F1 blocks terminal 
differentiation and induces proliferation in megakaryocytes, and the differentiation block 
imposed cannot be rescued by administration of platelet growth factors (79). 
Furthermore, short-term induction of an E2F3 transgene in the pituitary gland induces 
proliferation of quiescent melanotrophs (45)—indicating that long-term expression of 
deregulated E2F is not necessary to observe a biologically relevant effect. 
While short-term induction of E2F3 in the pituitary gland induces the 
proliferation of quiescent cells, long-term induction leads to the development of 
hyperplasia (45), and targeting transgenic expression of E2F1 or E2F3a to the epidermis 
and squamous epithelial tissues via the keratin 5 (K5) promoter also results in hyperplasia 
(80,81). Similarly, targeting transgenic E2F2 to the thymic epithelium results in 
hyperplasia (82). When targeted to the liver, transgenic E2F1 leads to pericentral large 
cell dysplasia (83), and conditional expression of E2F1 in the testes from an inducible 
promoter induces dyplasia that mimics carcinoma in situ—indicating that short-term E2F 
expression is sufficient to drive aberrant tissue proliferation in vivo (84).   
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In addition to the promotion of aberrant non-malignant tissue proliferation, 
transgenic expression of E2F can also lead to tumor development—either alone or in 
combination with other oncogenic mutations. In the presence of oncogenic ras or the 
absence of one or both p53 alleles, transgenic expression of E2F1 in K5 tissues leads to 
the development of skin tumors (80,85). Furthermore, K5 E2F1 transgenic mice are also 
prone to the spontaneous development of tumors in K5-expressing tissues as they age 
(40). In addition to dysplasia, transgenic expression of E2F1 in the liver also induces 
spontaneous tumor development (83), and targeting of E2F2 to the thymus epithelium 
can similarly induce tumor development in addition to hyperplasia (82). In the case of 
E2F3a, transgenic expression to K5 tissues increases the rate of spontaneous tumor 
development by 20% and additionally enhances tumor development in response to 
treatment with chemical carcinogens (81). Taken together, these studies demonstrate the 
ability in vitro and in vivo of deregulated E2F activity to promote cell proliferation in 
presence of antiproliferative signals, promote aberrant non-malignant tissue growth, and 
in some contexts, to promote tumorigenesis alone or in combination with other oncogenic 
mutations. 
 
Promotion of apoptosis 
 
 In addition to promoting cell cycle progression and oncogenic transformation, 
E2F1, E2F2 and E2F3a also have the ability to induce apoptosis, although there is 
significant disagreement as to the apoptosis-inducing ability of E2F2 and E2F3a 
(45,68,77,78,81,82,86,87). This is thought to act as a failsafe mechanism to counteract 
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the potential tumorigenicity associated with unrestrained E2F-mediated proliferation, and 
can occur in both p53 family-dependent and –independent mechanisms, which are 
described in detail in the section on E2F1 target genes. 
In cell culture-based experiments, ectopic overexpression of E2F1 in quiescent 
rodent fibroblasts by means of cDNA or adenovirus results in both S-phase entry and 
apoptosis (67,74,88,89). While the ability of E2F1 to induce apoptosis in vitro is quite 
clear, cell culture-based studies examining a role of E2F2 and E2F3a in E2F-induced 
apoptosis have yielded conflicting results. While one study reports no increase in 
apoptosis upon E2F2 or E2F3a overexpression (68), others have reported the contrary 
(86,87). Given this apparent contradiction, it is likely that the ability of E2F2 and E2F3a 
to induce apoptosis is highly context-dependent, whereas the ability of E2F1 is more 
ubiquitous. 
 The ability of E2F overexpression to induce apoptosis as observed in cell culture-
based assays is also evident in vivo by means of mice transgenic for E2F. In addition to 
E2F1 blocking differentiation and inducing proliferation when transgenicly targeted to 
megacaryocytes, significant megakaryocyte apoptosis is also observed (79). Likewise, 
when targeted to the liver or lens fiber, transgenic E2F1 induces proliferation as well as 
apoptosis (78), and an inducible E2F1 transgene targeted to the testes also promotes 
proliferation and apoptosis (84)—indicating that short-term deregulation of E2F1 is 
sufficient to drive apoptosis in vivo. Targeting of E2F1 to the K5 expressing epidermal 
tissues induces follicular apoptosis, and when crossed to a p53+/- or p53-/- background, 
E2F1-induced keratinocyte apoptosis is reduced (85)—indicating a role for the p53 tumor 
suppressor gene in E2F1-induced apoptosis. Oddly, when expressed under a non tissue-
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specific promoter, transgenic expression is only observed in the testicles and results in 
atrophy and sterility by means of increased apoptosis in the germinal epithelium (90). 
This however is independent of p53, as crossing these mice to a p53-/+ or p53-/- 
background does not result in decreased apoptosis (90). 
Similar results have also been obtained in mice transgenic for E2F2 or E2F3a. 
Trangenic expresion of E2F2 or E2F3a in the lens fiber promotes cell cycle reentry with 
subsequent apoptosis in postmitotic cells (77,78), yet there is no evident increase in 
apoptosis when E2F2 is targeted to the thymic epithelium (82), or when E2F3a is targeted 
to the pituitary gland (45). However, targeted expression of E2F3a to K5 tissues results in 
increased p53-independent apoptosis, as indicated by no decrease in the proportion of 
apoptotic cells when crossed to a p53-null background (81). As with in vitro-based 
studies examining a role for E2F2 and E2F3a in apoptosis induction, it is likely that their 
ability to induce apoptosis in vivo is also highly context dependent. It should also be 
noted that a recent study demonstrates that apoptosis induced by transgenic expression of 
E2F3a is dependent on E2F1 (91). In summary, under some contexts deregulated E2F, 
primarily E2F1, is capable of promoting apoptosis in addition to cell cycle progression 
though both p53-dependent and –independent pathways. 
 
Contradictory roles: promotion of growth arrest, tumor suppression, and survival 
 
 The previous sections discuss the ability of deregulated E2F to promote cell cycle 
progression, apoptosis, and oncogenesis, however it should be noted that under some 
contexts deregulated E2F can promote somewhat contradictory biological effects such as 
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growth arrest, tumor suppression, and cell survival (38-45). In cell culture-based assays, 
overexpression of E2F1 in primary fibroblasts can induce a growth arrest or checkpoint 
response that in some instances resembles a senescent-like state, which is dependent on 
the presence of one or more potent tumor suppressor genes such as p19ARF, p53, p21, 
p16INK4A, or Rb (42-45). Similarly, when transgenically targeted to the pituitary gland, 
E2F3 can induce an irreversible senescent-like state upon long-term exposure (45). 
However, reports of E2F-mediated growth arrest are sparse, and under most published 
contexts deregulated E2F induces proliferation. 
In the case of tumor suppression, overexpression of E2F1 in transformed mouse 
fibroblasts or normal human foreskin fibroblasts can reduce colony formation, and in the 
context of mouse fibroblasts, can abrogate focus formation induced by ras (38,39). The 
necessity of a functional tumor suppressor in this process is exemplified by the ability of 
dominant-negative p53 to abrogate the ability of E2F1 to suppress focus formation (39). 
While transgenic expression of E2F1 in K5 expressing tissues can lead to hyperplasia and 
the development of spontaneous tumors, it paradoxically suppresses tumor formation 
induced by treatment with a two-stage chemical carcinogenesis protocol (40). In 
agreement with studies describing the ability of E2F1 to induce growth arrest, tumor 
suppressors p53 and p19ARF are necessary for deregulated E2F1 to inhibit tumor 
formation in this context (41). 
In line with deregulated E2F having contradictory biological effects in the 
regulation of cell cycle progression and tumor development, deregulated E2F can also 
inhibit the induction of apoptosis under some contexts. As of yet this ability appears to be 
exclusive to instances of radiation-induced apoptosis, and is thought to facilitate DNA 
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repair (92,93). Transgenic expression of E2F1 to K5 expressing tissues suppresses 
epidermal apoptosis induced by UVB-irradiation in a p53-independent manner (92,93). 
Furthermore, K5 E2F1 transgenic mice display accelerated repair of UVB-induced DNA 
damage, indicating a role for E2F1 in promoting this type of DNA repair (92). While it is 
clear that deregulated E2F can promote growth arrest, tumor suppression, or survival 
under some contexts, it appears as though the requisite context is a normal cell absent of 
any losses of tumor suppressor function. Studies utilizing E2F loss-of-function models 
better describe these effects and lend further support to the idea that these contradictory 
biological effects are indeed important to normal physiology (94-99). However, the 
ability of deregulated E2F to inhibit cell growth, suppress tumor formation, and promote 
survival outside of the published contexts remains unclear.     
 
E2F target genes: connecting the biology of deregulated E2F to mechanisms 
 
E2F family proteins have been implicated in controlling the expression of genes 
involved in functions as diverse as DNA replication, the G1/S-phase transition, mitosis, 
DNA damage and repair, differentiation and development, and apoptosis (8,9,100). Some 
target genes have been thoroughly characterized by means of a comprehensive promoter 
analysis of E2F-mediated transactivation, or by inducing E2F activity in the presence of 
cyclohexamide, while others have been implicated in large-scale array-based analysis of 
E2F-induced transcripts or E2F-immunoprecipitated DNA. While a comprehensive 
review of all published E2F target genes involved in the many biological functions 
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attributed to E2F is beyond the scope of this manuscript, target genes relevant to the 
subsequent experimental data are discussed in detail. 
 
Mitotic targets of E2F 
 
 In addition to the well-characterized role of E2F-mediated transactivation of 
genes involved in the G1/S-phase transition and DNA replication, E2F has also been 
implicated in regulating the expression of cell cycle-associated genes with mitotic 
functions. Based on mircoarray analysis of transcripts, adenovirus-mediated 
overexpression of E2F1 or E2F2 in quiescent fibroblasts leads to the induction of a large 
subset of genes with mitotic functions, such as kifC1, cdc2, cyclin B and cdc20 (101). 
Strikingly, a comparison of E2F1 and E2F2 induced transcripts to temporal regulation of 
whole genome transcripts during the cell cycle reveals targets of E2F1 and E2F2 to be 
physiologically induced primarily at either the G1/S transition or during G2—suggesting a 
physiological role for E2F in the regulation of mitotic genes (101). While this study does 
not address whether the mitotic genes induced by E2F are direct or indirect targets, 
chromatin immunoprecipitation (ChIP) of E2F coupled to DNA microarray analysis 
reveals E2F present at the promoters of genes involved in chromatin assembly, 
condensation, and segregation, as well as the mitotic spindle checkpoint (102,103). 
A promoter based analysis of mitotic genes cell division control 2 (cdc2) and 
cyclin B1 reveals the presence of both positive and negative acting E2F elements, and 
that both E2F1 and E2F4 bind to the cdc2 and cyclin B1 promoters in vivo (104). 
Interestingly, E2F1 is only found at the cdc2 and cyclin B1 promoters during the G1/S-
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phase transition and S-phase, with E2F1 being completely disassociated by G2 (104). In 
addition to cdc2 and cyclin B1, the mitotic checkpoint protein mad2 is also a direct E2F1 
target gene, which couples deregulated E2F activity with the promotion of genomic 
instability (105). While a number of E2F targets with mitotic functions have been 
identified, only a handful have been characterized. Yet given the presence of E2F at the 
promoters of genes with mitotic functions, it would appear that E2F-mediated regulation 
is at least in part a direct mechanism. This presents as somewhat of a paradox, as E2F is 
thought to be no longer active when these genes are induced, and furthermore ChIP 
assays reveal E2F to be fully disassociated by G2 as well (104). While the precise 
mechanism by which E2F regulates the expression of genes with mitotic functions is yet 
to be determined, it is clear that E2F indeed plays a role that is in some instances direct. 
 
Apoptotic E2F targets and mechanisms 
 
 In addition to promoting cell cycle progression, E2F1 is also a potent inducer of 
apoptosis, and as such many transcriptional targets of E2F1 have functional roles in 
various stages of this process. Whereas few of the mitotic targets of E2F are well 
characterized, much more is known about transcriptional targets and mechanisms of 
E2F1-induced apoptosis. Indeed, E2F1 is implicated in the regulation of a multitude of 
genes with apoptotic functions; however the following will concentrate on the best-
characterized mechanisms. E2F1-induced apoptosis is generally categorized as occurring 
through either p53 family-dependent or p53 family-independent pathways by means of  
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Figure 4. Mechanisms of E2F1-induced apoptosis. E2F1 induces apoptosis through 
both p53 family-dependent and –independent pathways through both direct and indirect 
mechanisms. E2F1 indirectly stabilizes p53 by transactivation of p19ARF or ATM. While 
p19ARF inhibits the activity of negative p53 regulator Mdm2, ATM stabilizes p53 through 
phosphorylation. E2F1 can also induce the transcription of p53 homologue p73. E2F1 
directly induces the transcription of proapoptotic genes, such as Bok, Apaf-1 and PUMA, 
and can also directly repress the expression of prosurvival genes such as Mcl-1 and 
hTERT. 
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three primary mechanisms: the indirect stabilization of p53, the direct tranactivation of 
proapoptotic genes, and the direct repression of genes that promote cell survival (Fig. 4). 
While overexpression of E2F1 induces proapoptotic p53 (106), it does not do so 
directly and instead indirectly stabilizes p53 protein through two separate mechanisms. In 
a healthy cell, p53 activity is kept in check primarily at the level of protein stability. In 
response to cellular stress, E2F1 can directly induce the expression of p19ARF (68,107), 
which in turn binds to and inhibits the action of murine double minute 2 (Mdm2) 
(108,109). Mdm2 is an E3 ubiquitin ligase that targets p53 for degradation, and as such 
the end result of E2F1-mediated transactivation of p19ARF is stabilization of p53 
(110,111)—which leads to p53-mediated transactivation of proapoptotic genes. In 
addition to regulation of p53 protein stability via the ubiquitin-proteasome pathway, p53 
is also subject to stabilizing phosphorylations by stress-sensitive kinases. Stabilization of 
E2F1 in response to DNA damage results in E2F1-mediated direct tranactivation of 
Ataxia Telangiectasia-Mutated (ATM), which stabilizes p53 protein by phosphoylation at 
serine 15 (112,113). In addition to indirect stabilization of p53, E2F1 can also directly 
induce transcription of p53 homologue p73 (114,115), whose activation can induce 
apoptosis in a manner similar to that of p53.  
 In addition to p53-family dependent mechanisms of E2F1-induced apoptosis, 
E2F1 can also contribute to apoptosis through mechanisms independent of p53 family 
proteins. This can occur through two primary mechanisms: the direct transactivation of 
proapoptotic genes, and the direct or indirect repression of prosurvival genes. The use of 
microarray analysis of genes induced upon E2F1 overexpression, as well as array-based 
analysis of E2F1-bound DNA by ChIP, has implicated a multitude of potential apoptotic 
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targets of E2F1. However, what is unclear from these analyses is the relevance of these 
genes in E2F1-induced apoptosis. For this reason, the following will concentrate on those 
genes that are well characterized targets of E2F1. E2F1 directly induces the expression of 
multiple Bcl-2 homology (BH)3-only proteins including PUMA, Noxa, Bim, Bik, and 
Hrk/DP5 (116,117), proapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family members 
that function in the intrinsically-mediated apoptotic pathway to promote the release of 
cytochrome c and other mitotic factors from the mitochondria. In addition to BH3-only 
Bcl-2 family targets, E2F1 also directly transactivates the expression of proapoptotic Bcl-
2 family member Bok (118), which also functions to compromise mitochondrial 
membrane integrity. Other notable direct targets of E2F1 include Apoptosis activating 
factor-1 (Apaf-1) and Smac/DIABLO, as well as several caspases (119-121).   
 Contrary to targets and mechanisms in which E2F1 induces the expression of 
genes that promote apoptosis, E2F1 can intriguingly also repress the expression of genes 
with prosurvival functions through both direct and indirect mechanisms. E2F1 directly 
represses transcription of antiapoptotic Bcl-2 family member Myeloid cell leukemia-1 
(Mcl-1), which interestingly occurs in a pRb dependent manner, as deletion of the pRb-
binding/transactivation domain does not abrogate its ability (122). Similarly, E2F1 
directly represses the expression of human telomerase reverse transcriptase (hTERT), a 
gene involved in the maintenance of chromosome telomeres (123). In the death receptor 
mediated apoptotic pathway, TNF Receptor-Associated Factor 2 (TRAF2) inhibits 
apoptosis by stimulating antiapoptotic NF-kB. E2F1 can indirectly downregulate TRAF2 
at the level protein though an as yet uncharacterized mechanism, providing yet another 
example of inhibition of survival genes mediated by E2F1 (124). Taken together, the 
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preceding indicates that E2F1 plays a major role in regulating apoptosis through both p53 
family-dependent and –independent pathways functioning through multiple mechanisms. 
E2F targets and mechanisms involved in growth arrest, tumor suppression, and survival 
 
E2F targets and mechanisms involved in growth arrest, tumor suppression, and survival 
 
  As previously discussed, under certain contexts deregulated E2F can 
paradoxically promote survival, induce growth arrest, or contribute to tumor suppression 
(38-45). In many instances these biological effects are dependent on the presence of one 
or more tumor suppressors such as p19ARF, p53, p21, p16INK4A, or Rb (42-45). The 
mechanism by which E2F1 regulates p19ARF and ATM to ultimately control p53, as well 
as its direct ability to transactivate p73, has been thoroughly discussed in a previous 
section, however in addition to these mechanisms, other tumor suppressors are also direct 
targets of E2F. E2F can directly induce the transcription of CKIs p21, p27, and p57, 
suggesting a negative-feedback mechanism limiting the activity of E2F (125-127). As 
exemplified by ATM, E2F can also influence the expression of multiple genes with roles 
in the DNA damage response and checkpoint control (3,4,8,100,128). This however leads 
to a rather complex web of functions, as many E2F targets involved in the DNA damage 
checkpoint and DNA repair also play roles in apoptosis and general DNA synthesis. In 
summary, under certain contexts deregulated E2F can induce that transcription of genes 
that inhibit cell proliferation, promote survival, or suppress tumor formation, however the 
contexts determining preferential transcription of these genes remains to be further 
explored.  
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The RhoBTB2 (DBC2) putative tumor suppressor gene 
 
RhoBTB2, or Deleted in Breast Cancer 2 (DBC2) is a putative tumor suppressor 
gene located at 8p21 (129), a common spot for homozygous deletion in human 
malignancies arising from various tissues of origin (130-136). RhoBTB2 is the second 
member of a subclass within the Rho family of small GTPases proteins (RhoBTB1-3) 
and is highly divergent from other Rho family members. Orthologues of human RhoBTB 
genes are present in mammals, fish, flies and D. discoideum, yet orthologues are absent 
from the genomes of yeast and worms (129,137).  While only a handful of studies 
concentrating on RhoBTB2 have been published, the following describes what is 
currently known. 
 
Structure 
 
RhoBTB2 is composed of an N-terminal RhoGTPase domain, two broad-complex 
bric-a-brac/poxvirus zinc finger (BTB/POZ) domains, and a conserved C-terminal 
domain of unknown function. The RhoGTPase domain is highly homologous to that 
observed in other small GTP-binding proteins, and although it contains three putative 
GTP-binding motifs and a GTPase motif, studies indicate that it is incapable of GTP 
hydrolysis (138). In contrast to other members of the Rho family, RhoBTB2 contains a 
tandem of BTB/POZ domains, which are evolutionarily conserved domains thought to be 
involved in protein-protein interactions (139). BTB/POZ domains were first identified in 
Drosophila—where such proteins act as transcriptional repressors—yet many BTB/POZ 
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domain-containing proteins are encoded in the human genome (139). In humans, the 
BTB/POZ domains of RhoBTB2 as well as other proteins have been shown to interact 
with the Cullin 3 (Cul3) ubiquitin ligase complex, indicating a possible mechanism of 
regulation or action (140-144). 
 
Expression patterns 
 
During mouse embryogenesis, expression of RhoBTB2 mRNA is dependent on 
both tissue type as well as developmental stage (145). The highest levels of RhoBTB2 
expression in the developing mouse embryo are in nervous system tissues, where 
elevated levels of expression continue until embryonic day E16.5—when levels 
significantly decrease yet remain detectable throughout the remainder of development 
(145). The developing gut and liver also display temporal increases in RhoBTB2 
expression, yet surprisingly expression in the embryonic lung and mammary gland is 
very weak (145). This is intriguing, as deregulation of RhoBTB2 in human malignancy is 
best documented in cancers of the lung and breast (146). Human multi-tissue arrays 
reveal RhoBTB2 expression to be weak in most tissues except neural tissues (129), while 
another study finds RhoBTB2 expression present in noncancerous human breast, lung, 
brain, and placenta samples (146). Similarly, human fetal tissues show detectable 
RhoBTB2 expression in the lung, heart, and brain (129). Given the variability of 
expression patterns between studies and the deficiencies in quantification, it is difficult to 
make any concrete generalizations about RhoBTB2 expression patterns in developing or 
mature tissues. 
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Deregulation in human malignancy 
 
Alteration of RhoBTB2 in human malignancy has been described in the literature 
to occur by mean of deletion or loss of heterozygosity, downregulation, or point mutation 
(130-136,144,146). Indeed, RhoBTB2 was first characterized in humans by virtue of its 
deletion in primary breast cancer samples, where it is reported to be heterozygously 
deleted in 3.5% of cases (146). Deletions of RhoBTB2 have also been described in 
malignancies of the bladder, lung, ovary, and prostate (130-136), and ablation of 
RhoBTB2 expression through downregulation is reported to occur in approximately 50% 
of breast and lung cancers (146). In addition to deletion and downregulation, several 
point mutations have also been identified, with some of them effecting RhoBTB2 activity 
(144,146), although the biological significance of this is yet to be determined. These 
studies would seem to suggest that RhoBTB2 might behave as a tumor suppressor, and 
this idea is indeed supported by limited biological studies. 
 
Biological functions, mechanisms, and regulation 
 
Given the prevalence of RhoBTB2 alterations in human malignancy, one might 
suspect RhoBTB2 to behave biologically like a tumor suppressor, and indeed, the limited 
biological studies on RhoBTB2 support this hypothesis. Overexpression of RhoBTB2 in 
a breast cancer cell line with undetectable endogenous RhoBTB2 greatly inhibits 
proliferation, whereas overexpression in a cell line with endogenous RhoBTB2 has no 
effect on proliferation (146). Interestingly, overexpression of a BTB/POZ domain point-
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mutant RhoBTB2 construct derived from a human tumor (RhoBTB2-D299N) has no 
effect on proliferation, suggesting a role for the BTB/POZ domain in the mechanism of 
RhoBTB2-mediated cell cycle inhibition (146). In addition to inhibiting proliferation 
under certain contexts, RhoBTB2 has been linked to the microtubule motor complex, as 
knockdown of RhoBTB2 in 293 cells abrogates vesicular stomatitis virus glycoprotein 
transport (138). Taken together, these studies suggest that under some contexts, 
RhoBTB2 can function as a negative regulator of proliferation, and that RhoBTB2 has a 
functional role in transportation along the mictrotubule motor complex. However based 
on gain-of-function studies, it is not possible to classify RhoBTB2 as a tumor suppressor 
gene. A knockout mouse model is in order to fully examine the tumor suppressor 
capability of RhoBTB2. 
While the mechanism by which RhoBTB2 inhibits proliferation is not clear, 
downregulation of cyclin D1 has been proposed. Overexpression of RhoBTB2 in a cell 
line deficient of endogenous RhoBTB2 expression leads to inhibition of cell cycle and 
downregulation of cyclin D1 protein, and overexpression of cyclin D1 upon RhoBTB2 
overexpression ablates the ability of RhoBTB2 to inhibit proliferation (147). It is clear 
that RhoBTB2 overexpression decreases cyclin D1 protein, however the ability of 
enforced cyclin D1 overexpression to rescue cells from the inhibitory effect of RhoBTB2 
does not demonstrate the necessity of cyclin D1 downregulation to mediate this process. 
It is likely that the enforced overexpression of many positive regulators of cell cycle 
would result in a similar effect. With this in mind, it is not clear if downregulation of 
cyclin D1 is a mechanism by which RhoBTB2 inhibits proliferation; studies utilizing 
cyclin D1 deficiencies would better address this issue. A microarray-based network 
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analysis of transcripts influenced by RhoBTB2 deficiency and proficiency reveal 
RhoBTB2 to influence pathways responsible for cell cycle, apoptosis, cytoskeleton and 
membrane-trafficking, however the relevance of such conclusions is not clear (148). 
Taken together, while it is clear that RhoBTB2 influences the expression of various 
genes, the mechanisms by which RhoBTB2 inhibits proliferation and influences the 
microtubule motor complex remain uncertain.  
Only one physiological means of RhoBTB2 regulation has been reported in the 
literature, which involves degradation by the proteasome. RhoBTB2 binds to the Cul3 
ubiquiting ligase scaffold though its first BTB/POZ domain and is also a substrate for the 
Cul3 ubiquitin ligase complex, which targets RhoBTB2 for degradation (144). A 
RhoBTB2 construct derived from a lung cancer cell line containing a point mutation 
(Y284D) in the first BTB/POZ domain abolishes the ability of RhoBTB2 to bind Cul3, 
and thereby increases its expression due to decreased degradation. The authors present an 
attractive model in which the tumor suppressor function of RhoBTB2 is achieved via 
recruiting proteins to the Cul3 ubiquitin ligase, thus targeting them for proteasomal 
degradation; however this model is yet to be tested. 
 
Summary and rationale 
 
Given the prevalence of Rb-E2F pathway deregulation in human malignancy and 
the detrimental biological effects associated with unrestrained E2F activity, we sought to 
identify novel transcriptional targets of E2F1. In this manuscript, we identify RhoBTB2 
as a novel transcriptional target of E2F1. We demonstrate that overexpression of E2F1 
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directly activates RhoBTB2 expression, and that knockdown of E2F1 decreases the 
expression of RhoBTB2, thus indicating that E2F1-mediated activation of RhoBTB2 is 
physiologically relevant and not simply an artifact of overexpression. Furthermore, we 
show that RhoBTB2 is upregulated during mitosis as well as during drug-induced 
apoptosis, and that this activation is partially and primarily dependent on E2F1, 
respectively. Finally, we demonstrate that RhoBTB2 has active roles in E2F-mediated 
processes of cell cycle progression and apoptosis. Taken together, we describe RhoBTB2 
as a novel transcriptional target of E2F1 with roles in cell cycle and apoptosis. 
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Experimental Procedures 
 
Cell lines and cell culture 
 
The H1299 cell line was a gift from Dr. Jiandong Chen (Moffitt Cancer Center, 
Tampa, FL) and cultured in DMEM supplemented with 2 mM L-glutamine, 5% fetal 
bovine serum (FBS) and 1% penicillin/streptomycin (P/S). The MCF7 and MCF10A 
mammary fibrocystic cell lines were a gift from Dr. Richard Jove (City of Hope, Duarte, 
CA) and were cultured in DMEM-F12 supplemented with 2 mM L-glutamine, 10% FBS 
and 1% P/S. The T98G glioblastoma cell line was a gift from Dr. Joseph Nevins (Duke 
University, Durham, NC) and grown in DMEM supplemented with 2 mM L-glutamine, 
10% FBS, and 1% P/S. The H1299-pBS/U6 and H1299-shE2F1 cell lines were 
constructed and cultured as previously described (125,126,149). The H1299-ER-E2F1 
cell line was constructed and cultured as previously described (125,126,149,150). 
 
Adenovirus 
 
 The Ad-GFP and Ad-E2F1-GFP adenovirus were kind gifts from Dr. Timothy 
Kowalik (University of Massachusetts, Worchester, MA) (20,89). The Ad-E2F1(1-283)-
GFP adenovirus was constructed as previously described (42). The Ad-RhoBTB2-GFP 
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adenovirus was constructed using a cDNA construct of RhoBTB2 with an N-terminal 
3XFlag sequence and a C-terminal myc tag. The entire double-tagged sequence was used 
for virus construction with the AdEasy™ Adenoviral Vector System (Stratagene) using 
the pShuttle-IRES-hrGFP-1 vector following the manufacturer’s protocol. Titering was 
conducted using the AdEasy™ Viral Titer Kit (Stratagene). 
 
Real-time PCR 
 
Total cell RNA was harvested using the RNeasy Mini Kit (Qiagen) using the 
optional DNase treatment. Reverse Transcriptase (RT) reactions were random hexamer-
primed using Applied Biosystems’ (Foster City, CA) High Capacity cDNA Archive Kit. 
Standard curves were constructed using serial dilutions of pooled sample RNA (50, 10, 2, 
0.8, 0.4, and 0.08 ng) per reverse transcriptase reaction. One ‘no reverse transcriptase’ 
control was included for the standard curve and for each sample. 
TaqMan® Gene Expression Assays (Applied Biosystems) were used.  The assay 
primer and probe sequences are proprietary. TaqMan® probe Hs01598093_g1 was used 
for RhoBTB2. Real-time quantitative PCR analyses were performed using the ABI 
PRISM 7900HT Sequence Detection System (Applied Biosystems). All standards and 
samples were tested in triplicate wells. The no template control (H2O), no RT controls, no 
amplification control (Bluescript plasmid), and No RNA control were tested in duplicate 
wells. PCR was carried out with the TaqMan® Universal PCR Master Mix (Applied 
Biosystems) using 2 µl of cDNA and 1X primers and probe in a 20-µl final reaction 
mixture. After a 2-min incubation at 50°C, AmpliTaq Gold was activated by a 10-min 
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incubation at 95°C, followed by 40 PCR cycles consisting of 15s of denaturation at 95°C 
and hybridization of probe and primers for 1 min at 60°C. Data were analyzed using SDS 
software version 2.2.2 and exported into an Excel spreadsheet. The 18s data were used 
for normalizing gene values: ng gene/ng 18s per well. 
 
RhoBTB2 antibody production 
 
Affinity-purified rabbit polyclonal antibody was generated toward a peptide 
corresponding to human RhoBTB2 amino acids 673-687 (KEEDHYQRARKEREK) by 
Pacific Immunology (Ramona, CA).  Specifically, a 16-amino acid peptide 
(CKEEDHYQRARKEREK) was conjugated (via an artificial N-terminal cysteine 
residue) to Keyhole Limpet Hemocyanin and used to immunize rabbits.  Serum was 
subjected to peptide column affinity purification prior to use in immunofluorescence.  
Antibody specificity was demonstrated using a previously described RhoBTB2 siRNA 
(148). 
 
Plasmids, siRNA, and transfections 
 
RhoBTB2 siRNA was custom made (Ambion) using a previously published 
RhoBTB2 siRNA (DBC2-γ) sequence (148). siCONTROL non-targeting siRNA 
(Dharmacon) was used for all negative controls. The siRNA was transfected using 
Lipofectamine™ 2000 (Invitrogen) following the manufacturer’s protocol. The pBB14 
membrane GFP plasmid was a kind gift from Dr. L.W. Enquist (Princeton), constructed 
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as previously described (151) and transfected with Lipofectamine™ 2000 following the 
manufacturer’s protocol. 
 
Immunofluorescent microscopy 
 
Cells were grown on Lab-Tek® II Chamber Slides™ (Nunc), fixed with 4% 
paraformaldehyde, permeabilized with 0.5% Triton-X, then blocked with 2% BSA in 
PBS. The primary RhoBTB2 antibody was used at a 1:40 concentration, and the 
secondary antibody was Alexa Fluor® 555 goat anti-rabbit Ig antibody (Molecular 
Probes) at a concentration of 1:2000. Cover slips were mounted using ProLong® Gold 
antifade reagent with DAPI (Molecular Probes). Samples were viewed with a fully 
automated, upright Zeiss Axio- ImagerZ.1 microscope with a 40x or 63x /1.40NA oil 
immersion objective, and DAPI, FITC and Rhodamine filter cubes. Equal exposure times 
were used for each sample. Images were produced using the AxioCam MRm CCD 
camera and Axiovision version 4.5 software suite. 
 
Flow cytometry 
 
Cells were detached from culture plates via trypsin, washed twice with PBS, and 
then fixed in 70% ethanol. The fixed cells were washed twice with PBS and treated with 
RNase A and propidium iodide (PI). PI staining was used to measure for cell cycle status 
using a Becton-Dickinson FACScan instrument and Cell Quest software. 
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MTS assays 
 
For siRNA and adenovirus based experiments, the cells were first transfected or 
infected as described in the results section. After 24 hours of transfection or infection the 
cells were trypsinized, counted, and then plated in 96-well plates. The specific drug 
treatments were then administered and the MTS assays were conducted using a CellTiter 
96® AQueous One Cell Proliferation Assay Kit (Promega) following the published 
protocol. 
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Results 
 
E2F1 overexpression upregulates RhoBTB2 
 
Using a microarray screen, we sought to identify novel targets of the E2F1 
transcription factor. In this approach, we infected the H1299 cell line with adenovirus 
expressing either a green fluorescent protein control construct (Ad-GFP) or a GFP-fused 
E2F1 construct (Ad-E2F1-GFP). RNA was harvested at 24 and 48 hours and processed 
for microarray analysis. Among the list of genes whose transcripts were found to be 
highly induced by E2F1 infection was RhoBTB2. 
 To confirm the microarray results, we infected H1299s with either Ad-GFP, Ad-
E2F1-GFP, or Ad-E2F1(1-283)-GFP, a deletion mutant of E2F1 that is lacking the 
transactivation domain (45). Using real-time polymerase chain reaction (PCR) to quantify 
RhoBTB2 mRNA expression, we found that Ad-E2F1-GFP infection does indeed induce 
RhoBTB2 transcript approximately 5 and 20-fold compared to that of the Ad-GFP 
infection at the 24- and 48-hour time points, respectively (Fig. 5A). Lack of RhoBTB2 
activation by Ad-E2F1(1-283)-GFP infection confirms that upregulation of RhoBTB2 by 
E2F1 is dependent on E2F1’s C-terminal transcription activation domain. Since all 
experiments conducted to this point employed the H1299 cell line, we wanted to ensure 
that RhoBTB2 activation by E2F1 was not cell line-dependent. To this end, we infected 
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Figure 5. E2F1 overexpression upregulates RhoBTB2 mRNA. (A) H1299s were 
treated with either Ad-GFP, Ad-E2F1-GFP, or Ad-E2F1(1-283)-GFP adenovirus, 
harvested at 24 and 48 hours, with real-time PCR conducted to quantify RhoBTB2 
mRNA relative to 18S. (B, C) MCF7s or T98Gs were treated with either Ad-GFP or Ad-
E2F1 with subsequent real-time PCR analysis for RhoBTB2 to 18S at 24- and 48-hour 
time points. 
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the T98G and MCF7 cell lines with either Ad-GFP or Ad-E2F1 and conducted real-time 
PCR as in the prior experiment. We observed upregulation of RhoBTB2 similar to that 
which was observed in H1299s, thus confirming that RhoBTB2 upregulation by E2F1 
overexpression is not cell line specific (Fig. 5B, C). 
 In order to conduct protein-based studies of RhoBTB2, we raised a polyclonal 
antibody against a 15 amino acid peptide sequence located within the C-terminus. While 
the antibody was not able to recognize endogenous RhoBTB2 protein in a denatured state 
by western blot, we were able to visualize endogenous RhoBTB2 protein via 
immunofluorescenct microscopy (IFM) (Fig. 6A). To confirm that the observed signal 
was not an artifact of non-specific binding, we transiently knocked-down RhoBTB2 
expression using small inhibitory RNA (siRNA) and assayed for expression using IFM. 
As shown in Figure 6B, knock-down of RhoBTB2 expression diminishes the observed 
RhoBTB2 signal, thus confirming the specificity of the novel antibody. 
 Having an antibody functional for RhoBTB2 protein quantification, we sought to 
determine if the observed upregulation of RhoBTB2 mRNA by E2F1 overexpression 
resulted in a corresponding increase of RhoBTB2 at the protein level. To this end, an 
HA-tagged version of E2F1 (HA-E2F1), as well as a GFP-expression vector, were co-
transfected into H1299s. After 24 hours the cells were stained for RhoBTB2, and GFP 
positive and negative cells were used to select for transfected and non-transfected cells, 
respectively. We found that cells positive for GFP (transfected) expressed a substantially 
higher level of RhoBTB2 protein as compared to adjacent GFP-negative cells (Fig. 7), 
thus confirming that E2F1 overexpression results in increased expression of RhoBTB2 
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Figure 6. Novel RhoBTB2 antibody is functional in immunofluorescent microscopy 
and is specific for RhoBTB2. (A) Immunofluorescent microscopy (IFM) of H1299s at 
40x for RhoBTB2 with a rabbit polyclonal antibody described in experimental 
procedures—DAPI: blue; RhoBTB2: red. (B) IFM as in 6A of H1299s transfected with 
either negative control siRNA (top) or siRNA to RhoBTB2 (bottom) after 48 hours. 
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protein. Taken together, these results demonstrate that RhoBTB2 is upregulated at both 
the mRNA and protein levels by E2F1 overexpression. 
 
Upregulation of RhoBTB2 by E2F1 is direct and not dependent on artificial 
overexpression 
 
We considered the possibility that RhoBTB2 might be an indirect target of E2F1; 
to address the issue of direct versus indirect activation, we utilized a well characterized 
H1299 cell line with an estrogen receptor-fused version of E2F1 stably integrated (H1299 
ER-E2F1) (125,126,149,150). The result is an overexpressed version of E2F1 that is 
transcriptionally inactive due to estrogen receptor-mediated cytoplasmic localization. 
Using this system, E2F1 activity can be rapidly induced through nuclear localization by 
addition of the estrogen receptor ligand 4-hydroxytamoxifen (4-OHT), while 
simultaneously blocking new protein synthesis by means of cyclohexamide (CHX). Any 
transcripts found to be induced by 4-OHT in the presence of CHX can be considered 
direct E2F1 targets. 
 As shown in figure 8, RhoBTB2 mRNA expression is relatively low in the 
untreated H1299 ER-E2F1 cell line, as well as after 8 and 24 hours of treatment of CHX 
alone. As expected, upregulation of RhoBTB2 is readily observed at 8 and 24 hours after 
promoting E2F1 nuclear localization through treatment with 4-OHT. This activation of 
RhoBTB2 transcription by 4-OHT is not abrogated upon co-administration of CHX, thus 
confirming that RhoBTB2 is a direct transcriptional target of E2F1. 
RhoBTB2DAPI MergeGFP
Transfection:
HA-E2F1 + GFP
 
 
 
 
Figure 7. E2F1 overexpression upregulates RhoBTB2 protein. IFM at 63x of two 
different fields of H1299s 48 hours after being transiently cotransfected with pcDNA3-
HA-E2F1 and pBB14, a membrane GFP plasmid—DAPI: blue; GFP (transfected cells): 
green; RhoBTB2: red. 
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Figure 8. E2F1-mediated upregulation of RhoBTB2 is direct. The H1299-ER-E2F1 
cell line was treated with either CHX, 4-OHT or both. Cells were harvested for real-time 
PCR analysis at 8- and 24-hour time points. 
42 
43 
Having shown the capability of artificially overexpressed E2F1 to directly 
activate RhoBTB2, we next sought to determine if E2F1 plays a role in RhoBTB2 
regulation under physiological conditions. To this end, we employed H1299 cell lines 
with a stably integrated short-hairpin inhibitory RNA corresponding to E2F1 (H1299-
shE2F1) or an empty vector control (H1299-pBS/U6) (125,126,149). We observed 
significant knockdown of E2F1 in the H1299-shE2F1 in comparison to the H1299-
pBS/U6 as previously reported (Fig. 9A) (125,126,149).  We stained the cells for 
RhoBTB2 and compared expression levels between the two lines by means of IFM. The 
H1299-pBS/U6 control cell line with unaltered E2F1 expressed RhoBTB2 at levels 
comparable to that of the parental H1299 line (Fig. 9B). In contrast, the H1299-shE2F1 
cell line displayed greatly diminished expression of RhoBTB2 when compared to that 
observed in the H1299-pBS/U6 cell line (Fig 9B). Given that knock-down of E2F1 
diminishes RhoBTB2 expression, we conclude that E2F1 is indeed a physiological 
regulator of RhoBTB2. 
 
RhoBTB2 is upregulated during mitosis, which is partially dependent on E2F1 
 
One of the main functions of the growth promoting E2Fs is to activate the 
transcription of genes critical for cell cycle progression (8,9). Having identified 
RhoBTB2 as an E2F1 target gene, we postulated that RhoBTB2 expression may be 
regulated through this process. To examine RhoBTB2 expression through the cell cycle, 
we stained an asynchronously growing population of H1299s for RhoBTB2 and 
examined the population for cells in interphase as well as various stages of mitosis via 
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Figure 9. RhoBTB2 is a physiological target of E2F1. (A) A western blot for E2F1 in 
the H1299-pBS/U6 and H1299-shE2F1 cell lines demonstrating efficient knockdown of 
E2F1. (B) IFM at 63x using the RhoBTB2 polyclonal antibody conducted on 
asynchronously growing H1299-pBS/U6 and H1299-shE2F1 cell lines—DAPI: blue; 
RhoBTB2: red 
44 
45 
IFM. As shown in figure 10, H1299s in interphase express a relatively low level of 
RhoBTB2; however, upon the initiation of prophase RhoBTB2 levels increase 
dramatically. RhoBTB2 expression remains highly elevated through metaphase and 
anaphase, and does not begin to decrease until telophase/cytokinesis. 
A vast majority of cancers exhibit aberrant regulation of the RB-E2F pathway, 
with the end result being unrestrained E2F molecules. We considered the possibility that 
the observed mitotic upregulation of RhoBTB2 may be an artifact of the highly 
transformed H1299 phenotype. To address this issue, we conducted identical experiments 
in MCF10As, a non-tumorigenic mammary fibrocystic cell line. In these experiments we 
observed mitotic upregulation of RhoBTB2 that parallels that observed in H1299s (Fig. 
10), confirming that upregulation of RhoBTB2 during mitosis is not due to the highly 
transformed nature of H1299s. 
We next wanted to determine if the observed mitotic upregulation of RhoBTB2 
was dependent upon E2F1. We utilized the aforementioned E2F1 proficient and 
knockdown cell lines H1299-pBS/U6 and H1299-shE2F1 to compare cell cycle 
regulation of RhoBTB2 in cells with two different levels of E2F1 expression. 
Asynchronously growing populations of the two cell lines were stained for RhoBTB2 and 
examined for cells in interphase and various stages of mitosis as previously described. As 
expected, mitotic upregulation of RhoBTB2 was readily observed in the H1299-pBS/U6 
cell line, and was comparable to that seen in the parental H1299s (Fig. 11, top panel). 
During interphase, the H1299-shE2F1 cell line has lower basal expression of RhoBTB2, 
as previously observed. However, we noted an impaired mitotic upregulation of 
RhoBTB2 in the H1299-shE2F1 cell line (Fig. 11, bottom panel). While there is an 
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Figure 10. RhoBTB2 is upregulated during mitosis. IFM at 63x using the RhoBTB2 
polyclonal antibody of representative H1299s (top) and MCF10A (bottom) cells in either 
interphase, prophase, metaphase, anaphase, or telophase/cytokinesis within 
aynchronously growing populations—DAPI: blue; RhoBTB2: red. 
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Figure 11. Mitotic upregulation of RhoBTB2 is partially dependent on E2F1. IFM at 
63x using the RhoBTB2 polyclonal antibody of representative H1299-pBS/U6 (top) and 
H1299-shE2F1 (bottom) cells in either interphase, prophase, metaphase, anaphase, or 
telophase/cytokinesis within aynchronously growing populations—DAPI: blue; 
RhoBTB2: red. 
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evident upregulation of RhoBTB2 during prophase, it is significantly impaired when 
compared to that observed with the E2F1 proficient H1299-pBS/U6 cell line. This trend 
of diminished mitotic upregulation of RhoBTB2 continues to be observable throughout 
all of the mitotic phases examined (Fig. 11). We postulate that residual regulation 
ofRhoBTB2 may be mediated by additional E2F family members. Taken together, this 
demonstrates that RhoBTB2 is indeed upregulated during mitosis, which is partially 
dependent on the presence of E2F1. 
 
Overexpression of RhoBTB2 increases the S-phase fraction and slows proliferation 
 
Given the observation that RhoBTB2 is upregulated during M-phase of the cell 
cycle, we sought to determine if artificial manipulation of RhoBTB2 levels would have a 
functional and observable effect on cell cycle status or proliferation. To this end, we 
constructed an adenovirus expressing either GFP (Ad-GFP) or RhoBTB2 fused to an 
internal ribosome entry site (IRES) GFP construct (Ad-RhoBTB2-GFP). Asynchronously 
growing H1299s were then infected with equal amounts of either Ad-GFP or Ad-
RhoBTB2-GFP and harvested at 48 hours for flow cytometric analysis of cell cycle status 
via propidium iodide (PI) staining. As shown in figure 12A, overexpression of RhoBTB2 
alters the cell cycle status of H1299s by increasing the fraction of cells in S-phase. 
Having noted that overexpression of RhoBTB2 increased the S-phase fraction; we 
wanted to know how this single snap shot of cell cycle status manifested in a functional 
effect on cell proliferation. To test this, we infected asynchronously growing H1299s 
with either Ad-GFP or Ad-RhoBTB2-GFP adenovirus and conducted MTS-based 
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Figure 12. Overexpression of RhoBTB2 increases the S-phase fraction and slows 
proliferation. (A) The H1299 cell line was infected in triplicate with equal amounts of 
either the Ad-GFP or Ad-RhoBTB2-GFP adenovirus and harvested 48 hours post-
infection for flow cytometry. Propidium Iodide was used to analyze cell cycle status. (B) 
H1299s were infected in triplicate with equal amounts of either the Ad-GFP or Ad-
RhoBTB2-GFP adenovirus, detached at 24 post-infection, counted, and transferred to 96 
well plates where an MTS assay was performed to analyze cell proliferation after 24, 48 
and 72 hours. 
48 
49 
proliferation assays. As shown in figure 12B, cells infected with RhoBTB2 adenovirus 
exhibited impaired cell proliferation over multiple passages as compared to those infected 
with the control GFP virus. Since we observed an increase in the S-phase fraction as well 
as slowed cell progression upon overexpression of RhoBTB2, we wanted to determine 
ifsiRNA-mediated knockdown of RhoBTB2 would alternatively decrease the S-phase 
fraction or increase the rate of proliferation. We found that depletion of RhoBTB2 did not 
alter the cell cycle status or the rate of proliferation, consistent with the idea of RhoBTB2 
as being a negative regulator. From these observations, we conclude that the observed 
increase in the S-phase fraction upon overexpression of RhoBTB2 is potentially caused 
by a transient S-phase arrest or lengthened S-phase. 
 
RhoBTB2 is upregulated during drug-induced apoptosis, which is primarily dependent on 
E2F1 
 
E2F1 is unique among the E2F family members in that it not only has the ability 
to transactivate genes critical for cell cycle progression, but is also a potent inducer of 
apoptosis through activating the transcription of proapoptotic genes (for review, see ref. 
(24)). Given this fact, we investigated whether RhoBTB2 expression was effected by 
drug-induced apoptosis. To determine whether RhoBTB2 is regulated by apoptotic 
insults, we treated H1299s with either cisplatinum, flavopiridol or etoposide, 
chemotherapeutic agents where E2F1 is known to be a critical mediator, and conducted 
IFM to determine whether these cytotoxic insults had any effect on RhoBTB2 expression. 
As shown in figure 13A, we observed that administration of all of the chemotherapeutic 
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Figure 13. RhoBTB2 is upregulated during drug-induced apoptosis. IFM at 63x 
using the RhoBTB2 polyclonal antibody of representative cells from H1299s after 24 
hours of either no treatment, 20 uM cisplatinum, 200 nM flavopiridol, or 20 uM 
etoposide—DAPI: blue; RhoBTB2: red. 
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agents tested resulted in increased RhoBTB2 protein expression, with flavopiridol 
exhibiting the weakest. 
 While we observed upregulation of RhoBTB2 during cytotoxic insult, we wanted 
to determine if E2F1 was responsible for this upregulation. To examine this issue, we 
utilized the previously described E2F1 proficient and knockdown cell lines H1299-
pBS/U6 and H1299-shE2F1 and conducted IFM on cells treated with the aforementioned 
apoptotic stimuli. As previously observed, RhoBTB2 expression was diminished in the 
untreated H1299-shE2F1 cell line compared to the control H1299-pBS/U6 cell line (Fig. 
14A). Upon the induction of apoptosis, the control H1299-pBS/U6 cell line behaved 
similar to that of the parental H1299s, with upregulation of RhoBTB2 being clearly 
evident after 24 hours (Fig. 14, top). In stark contrast, we observed very little 
upregulation of RhoBTB2 in the H1299-shE2F1 cell line (Fig. 14A, bottom). Figure 14C 
displays E2F1 protein levels at 24 hours post treatment, demonstrating that E2F1 
upregulation does not occur in the H1299-shE2F1 cell line even in the presence of 
cytotoxic insult. It should be noted that in the presence of flavopiridol, we observe 
upregulation of E2F1 to be highest shortly after treatment (around 6 hours) and 
diminished by 24 hours, which explains the seemingly diminished E2F1 expression as 
compared to the no treatment control. Taken together, these results demonstrate that 
RhoBTB2 is upregulated during drug-induced apoptosis, and that this upregulation is 
primarily dependent on the presence of E2F1. 
 
 
 
 
 
 
 
 
 
 
 
H1299-
shE2F1
H1299-
pBS/U6
No Treatment Cisplatinum Flavopiridol Etoposide
No
 Tr
eat
me
nt
Cis
pla
tin
um
Fla
vop
irid
ol
Eto
po
sid
e
No
 Tr
eat
me
nt
Cis
pla
tin
um
Fla
vop
irid
ol
Eto
po
sid
e
H1299-shE2F1H1299-pBS/U6
A
B
DAPI   
52 
RhoBTB2
 
 
 
 
 
 
 
 
 
 
Figure 14. Upregulation of RhoBTB2 during drug-induced apoptosis is primarily 
dependent on E2F1. (A) IFM at 63x using the RhoBTB2 polyclonal antibody of 
representative H1299-pBS/U6 (top) or H1299-shE2F1 (bottom) cells after 24 hours of 
either no treatment, 20 uM cisplatinum, 200 nM flavopiridol, or 20 uM etoposide—
DAPI: blue; RhoBTB2: red. 
53 
Knockdown of RhoBTB2 expression by siRNA impairs the induction of drug-induced 
apoptosis 
 
Previous experiments demonstrated that RhoBTB2 is upregulated during drug-
induced apoptosis in an E2F1-dependent manner; we therefore wanted to explore whether 
disruption of RhoBTB2 activity would have a functional effect on drug-induced 
apoptosis. To address this issue, we transiently depleted RhoBTB2 in H1299s via siRNA-
mediated knockdown of RhoBTB2, induced apoptosis using the drug treatments 
previously employed, and conducted MTS assays to measure cell viability over the span 
of three days. While loss of viability occurred in both the siControl and siRhoBTB2 
transfected cell lines upon cytotoxic drug treatment, this loss of viability was abrogated in 
cells lacking RhoBTB2 (Fig. 15). We observed similar results in all drug treatments used, 
implying that RhoBTB2 may play a more ubiquitous role in apoptosis. Since we observed 
abrogated induction of apoptosis in upon siRNA-mediated knockdown of RhoBTB2, we 
wanted to determine if overexpression of RhoBTB2 would alternatively hasten the 
induction of apoptosis. We found that adenovirus-mediated overexpression of RhoBTB2 
did not hasten the induction of apoptosis. We interpret these data as for the first time 
demonstrating that RhoBTB2 plays a direct and important role in the implementation of 
apoptosis. 
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Figure 15. Knockdown of RhoBTB2 via siRNA impairs the induction of drug-
induced apoptosis. H1299s were transiently transfected with either a negative control 
siRNA, or siRNA against RhoBTB2, detached at 24 post-transfection, counted, and 
transferred to 96 well plates where an MTS assay was performed to analyze cell viability 
after 24, 48 and 72 hours of treatment with either 20 uM cisplatinum (A), 200 nM 
flavopiridol (B), or 20 uM etoposide (C). 
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Discussion 
 
E2F is perhaps best known for its ability to promote the transcription of genes 
involved in the G1/S-phase transition; however an increasing amount of evidence 
implicates a role for E2F in the regulation of genes with mitotic functions. 
Overexpression of E2F1 or E2F2 induces a subset of genes with mitotic functions, and 
E2F1 can be found at the promoters of genes with mitotic functions (101-105). 
Furthermore, targets of E2F1 and E2F2 tend to be physiologically regulated temporally at 
two distinct cell cycle stages: G1/S and G2, implicating a role for E2F-mediated 
transcription long after E2F is thought to be inactive (101). 
While a number of mitotic E2F targets have been identified, few have been 
characterized. In this work, we demonstrate that RhoBTB2 is a direct target of E2F1 that 
is physiologically upregulated during mitosis. We further show that mitotic upregulation 
of RhoBTB2 is partially dependent of E2F1, as knockdown of E2F1 expression via 
shRNA abrogates mitotic upregulation of RhoBTB2. It is possible that the remaining 
mitotic upregulation of RhoBTB2 in the absence of E2F1 is dependent on E2F2 or 
E2F3a; however we have not pursued this hypothesis. 
  In addition to being a mitotic target of E2F1, we also find that RhoBTB2 is an 
apoptotic target of E2F1 as well. RhoBTB2 is upregulated upon treatment with 
chemotherapeutic drugs, which is primarily independent on E2F1 as knockdown of E2F1 
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with shRNA abrogates this effect as well. We see a greater dependence on E2F1 for 
apoptosis-induced upregulation as opposed to mitotic upregulation, and this may be due 
to an inability of E2F2 or E2F3a to compensate, as E2F1 is the primary inducer of 
apoptosis among the activating E2Fs.  
 In order to further explore the significance of E2F-mediated regulation of 
RhoBTB2, we examined a functional role for RhoBTB2 in either of these processes. 
Overexpression of RhoBTB2 increases the fraction of cells in S-phase and significantly 
impairs cell proliferation, which we interpret as possibly being a transient S-phase block, 
as we only see a partial block in cell proliferation. In the case of apoptosis, we find that 
depletion of RhoBTB2 by siRNA slows the induction of drug-induced apoptosis. While 
deciphering mechanisms by which RhoBTB2 acts in cell cycle inhibition and the 
induction of apoptosis was beyond the scope of this study, published reports on 
RhoBTB2 have led to some intriguing hypotheses. 
 In agreement with our observations, RhoBTB2 was shown to inhibit cell 
proliferation in a breast cancer cell line deficient for RhoBTB2 (146). Futher studies 
asserted that RhoBTB2-mediated downregulation of cyclin D1 was obligatory for this 
effect (147). Another study utilizing pathway-based analysis of gene expression patterns 
found RhoBTB2 to effect the expression of genes associated with cell cycle, apoptosis, 
cytoskeleton and membrane-trafficking pathways (148). But perhaps the most intriguing 
study of found that RhoBTB2 direct bound and was a substrate of the Cul3 ubiquitin 
ligase (144). The authors proposed a hypothesis in which RhoBTB2 served as a scaffold 
that recruited proteins to the Cul3 complex to be targeted for degradation. This seems 
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quite rational, as other BTB/POZ domain-containing proteins have similar functions 
(140-144). 
  Given the previously mentioned studies coupled with our own observations, we 
believe that the functional significance of E2F1-mediated upregulation of RhoBTB2 
could be directly related to the ability of RhoBTB2 to recruit proteins to the Cul3 
complex to be targeted for degradation. We propose a model in which the physiological 
role of RhoBTB2 in mitosis and apoptosis is to recruit proteins to the Cul3 complex to be 
targeted for degradation, and that the cell cycle inhibition observed during overexpression 
may be a non-physiological response from RhoBTB2 targeting proteins to Cul3 in phases 
of the cell cycle where RhoBTB2 would not normally be present (Fig. 16). While cyclin 
D1 would seem like an attractive candidate to mediate this effect, one would not expect 
to see an arrest occurring in S-phase or G2/M upon loss of cyclin D1. Additionally, 
cyclin D2 or D3 might be expected to compensate. While the mechanisms behind the 
biological functions of RhoBTB2 are yet to be determined, it is clear that RhoBTB2 is 
indeed a physiologically relevant direct target of E2F1. 
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Figure 16. A proposed mechanistic model for RhoBTB2 activity. In this model, we 
propose that RhoBTB2 exerts its cell cycle and apoptotic biological effects by facilitating 
uibiquitination and subsequent degradation of cell cycle and apoptosis regulatory 
proteins. We propose that RhoBTB2 acts as a substrate-specific adaptor for the Cul3 
ubiquitin ligase.
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PART II 
 
IDENTIFICATION AND CHARACTERIZATION OF TWO NOVEL MCL-1 
PROMOTER POLYMORPHISMS 
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Abstract 
 
A publication from Moshynska et al. identified two novel sequence variants of the 
MCL-1 promoter within lymphocytes from chronic lymphocytic leukemia patients 
(CLL), but not within noncancerous tissue from the same individuals or in lymphocytes 
from 18 healthy control subjects (1). This result suggested that the variants—insertions of 
6 or 18 nucleotides at position –188 relative to the transcription start site—were CLL-
related somatic oncogenic mutations. Moshynska et al. also determined that the 6- and 
18-nucleotide insertions were associated elevated Mcl-1 expression, and proposed that 
the variant promoters could be used as a prognostic marker. We independently identified 
and cloned the three observed sequence variants from cancer cell lines hereby referred to 
as the Mcl-1 +0, +6 or +18 promoters. In contrast to Moshynska et al., we find the variant 
promoters to be identically present in both cancerous and adjacent noncancerous clinical 
lung samples, suggesting that the variants are germ-line encoded. We also find the three 
variant promoters prevalent in genomic DNA derived from healthy control samples and 
present at frequencies similar to that observed in cancerous cell lines. Furthermore, 
activity analysis of the three variant promoters reveals the Mcl-1 +6 and +18 promoters 
to be less active than the Mcl-1 +0 promoter, both during normal cellular homeostasis 
and under conditions that actively induce Mcl-1 transcription. Given our results, we 
61 
conclude that the Mcl-1 +6 and +18 promoters are likely benign polymorphisms and do 
no represent a reliable prognostic marker. 
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Introduction 
 
Mcl-1 and the Bcl-2 family of proteins 
 
Mcl-1 is an antiapoptotic member of the Bcl-2 family of proteins. The Bcl-2 
family is a group of proteins involved in the intrinsic stress-mediated apoptotic pathway 
whose primary role is to regulate the release of cytochrome c and other apoptotic factors 
from the mitochondria and possibly the endoplasmic reticulum (ER) (152,153). Upon 
release from the mitochondria, cytochrome c forms a complex with Apaf-1 which cleaves 
and activates effector caspases, thus initiating apoptosis (154,155). The Bcl-2 family is 
divided into three subfamilies that play distinct roles in both promoting and inhibiting the 
integrity of the mitochondrial membrane and ultimately—the release of cytochrome c and 
the initiation of apoptotsis. These subfamilies consist of the proapoptotic BH3-only 
subfamily, the antiapoptotic Bcl-2 subfamily, and the proapoptotic Bax subfamily. The 
roles of each family member in the intrinsic apoptotic pathway are illustrated in figure 
17. 
 
 
 
 
 
 
 
 
 
 
Cellular 
Stress
BH3-only
Bcl-2
Bax
Cytochrome c 
Release  
 
 
 
 
 
 
Figure 17. The Bcl-2 family and the intrinsic stress-induced apoptotic pathway. 
Cellular stress activates proapoptotic BH3-only Bcl-2 subfamily members through 
various mechanisms. BH3-only subfamily members block the ability of antiapoptotic 
Bcl-2 subfamily members to restrain the activity of proapoptotic Bax subfamily 
members. This leads to oligomerization of Bax subfamily members in the mitochondrial 
membrane, which promotes the release of cytochrome c and other apoptotic factors, thus 
initiating apoptosis. 
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The BH3-only subfamily 
 
 The BH3-only subfamily consists of multiple family members that are the first 
responders to cellular stress within the intrinsic apoptotic pathway (Fig. 13). Depending 
on the nature of the cellular stress, individual or multiple BH3-only proteins may become 
activated. Activation can occur through transcriptional regulation, post-translational 
modification, or both, and is largely family member-dependent. These subfamily 
members are proapoptotic, and promote the release of apoptotic factors from the 
mitochondria. While there is significant disagreement as to the exact mechanism by 
which Bcl-2 family members interact to disrupt mitochondrial membrane integrity, it can 
be generally stated that the primary role of the BH3-only proteins is to antagonize the 
inhibitory action of antiapoptotic Bcl-2 family members through direct binding. Indeed, 
the BH3-only family is named such due to the presence of a single BH3 domain which, 
depending on the subfamily member, binds to the receptor domain of one or more 
antiapoptotic Bcl-2 subfamily proteins (152,153). 
 
The Bcl-2 subfamily 
 
 The second subfamily within the Bcl-2 family is the Bcl-2 subfamily, and their 
primary role is to promote cell survival. Like the BH3-only subfamily, the Bcl-2 
subfamily consists of multiple members; however the most notable and likely most 
relevant members are Bcl-2, Mcl-1 and Bcl-xL. Bcl-2 subfamily proteins act downstream 
of BH3-only proteins and, in the absence of activated BH3-only proteins, maintain  
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mitochondrial membrane integrity at least in part by antagonizing the activity of Bax 
subfamily members. Structurally, Bcl-2 subfamily members contain a transmembrane 
domain (TM), and BH1-4 domains. The TM domain is thought to function as an anchor 
for integration into the membranes of the mitochondria and endoplasmic reticulum, and 
BH1, BH2 and BH3 domains collectively form a receptor domain specific for the BH3 
motif. In the absence of cellular stress, Bcl-2 subfamily proteins are thought to restrain 
the proapoptotic activity of Bax subfamily proteins at least in part through direct binding 
of the Bcl-2 receptor domain to the BH3 domain of Bax subfamily members. However in 
the presence of cellular stress and activated BH3-only proteins, the BH3 domain of BH3-
only proteins is thought to directly bind to the receptor domain of Bcl-2 subfamily 
members and prevent Bcl-2 subfamily members from restraining the activity of Bax or 
Bak (152,153). 
 
The Bax subfamily 
 
The final subfamily within the Bcl-2 family is the proapoptotic Bax subfamily, 
which consists of only two members: Bax and Bak. Bax and Bak are thought to be 
functionally redundant, as inactivation of either family member alone has little effect on 
apoptotsis, while inactivation of both significantly inhibits apoptosis (156). Structurally, 
Bax and Bak contain a TM domain and BH1-3 domains. Cellular stress induces Bax and 
Bak to make a conformational change and form homo-oligomers within the 
mitochondrial membrane. Oligomerization of Bax and Bak in the mitochondrial 
membrane disrupts membrane integrity and promotes the release of apoptotic factors. The 
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mechanism by which oligomerized Bax and Bak compromises mitochondrial membrane 
integrity has not been fully elucidated, although several models have been proposed 
(152,153). 
 
Mcl-1 is an inhibitor of apoptosis 
 
As illustrated in the previously described model, the physiological role of Mcl-1 
and other antiapoptotic subfamily members is to promote survival through the 
maintenance of mitochondrial membrane integrity (Fig. 13). This function is well 
documented in both cell culture-based and in vivo experiments utilizing both gain-of-
function and loss-of-function techniques. While the experiments that lend support for this 
model of activity are best described for Bcl-2, studies focusing on Mcl-1 will be the topic 
of discussion in the following paragraphs.  
 In cell culture-based assays, Mcl-1 overexpression inhibits the induction of 
apoptosis in multiple models, and is exemplified by the ability of overexpressed Mcl-1 to 
inhibit apoptosis induced by staurosporin or transient c-Myc overexpression in Chinese 
hamster ovary cells (157,158). Additionally, in murine myeloid progenitor cells, 
overexpression of Mcl-1 delays apoptosis induced by cytotoxic agents or growth factor 
withdrawal (159). In agreement with in vitro studies, transgenic expression of Mcl-1 in 
hematolymphoid tissues results in increased viability in various cells of lymphoid and 
myeloid origin—occuring at both mature and immature stages of development (160,161). 
Transgenic expression of Mcl-1 also promotes the development of certain hyperplasias 
and malignancies, which may be the result of an inhibition of apoptosis (160,162). 
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Studies dealing with the effects of deregulated Mcl-1 expression on aberrant tissue 
proliferation are addressed in more detail in the section regarding Mcl-1 and oncogenic 
transformation.  
 Similar to overexpression studies, depletion of Mcl-1 by means of antisense RNA 
or siRNA in cell culture assays can either promote spontaneous apoptosis or sensitize to 
apoptosis. This effect is well documented and holds true in multiple in vitro model 
systems. Indeed, several studies demonstrate the feasibility of utilizing siRNA against 
Mcl-1 as a therapeutic intervention in malignancy (163-166). Since disruption of both 
Mcl-1 alleles in mice results in peri-implantation embryonic lethality (167), various 
targeted disruptions have been developed to examine the role of disrupted Mcl-1 
expression in vivo. Targeted deletion of Mcl-1 in the T or B cell lineages results in a 
significant reduction of B and T lymphocytes, and when deleted in the same lineage 
during lymphocyte development, increased apoptosis and developmental arrest is 
observed (168). Furthermore, deletion of Mcl-1 in mature lymphocytes leads to a loss of 
viability (168). Induced deletion of Mcl-1 in mature mice leads to depletion of the bone 
marrow due to decreased cell survival (169), and targeted deletion to macrophages and 
neutrophils results in decreased neutrophil survival as manifested by an increased rate of 
apoptosis in granulocytic compartments (170). Collectively, these experiments describe 
the crucial role that Mcl-1 plays in regulating apoptosis both in vitro and in vivo. 
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Mcl-1 and oncogenic transformation 
 
One of the defining features of malignant transformation is an ability to evade 
apoptotic signals. Given Mcl-1’s potent ability to promote survival, it is not surprising 
that Mcl-1 can contribute to oncogenic transformation under certain contexts. Much of 
the support for this stems from experiments utilizing mice transgenic for Mcl-1. Long-
term expression of transgenic Mcl-1 targeted to hematolyphoid tissues results in the 
development of B-cell lymphoma (160), and explantation and culture of myeloid cells 
derived from Mcl-1 transgenic mice in the presence of interleukin (IL)-3 can induce 
immortalization (161). Additionally, transgenic expression of murine Mcl-1 leads to islet 
cell hyperplasia (162). It is unlikely that Mcl-1 action alone is sufficient for oncogenic 
transformation and likely cooperates with one or many oncogenic mutations to promote 
characteristics of a malignant phenotype. It is clear however, that under the proper 
conditions, enforced Mcl-1 expression can contribute to the development of an oncogenic 
phenotype. 
 
Mechanisms regulating Mcl-1 expression 
 
Mcl-1 expression is regulated at multiple levels including regulation of 
transcription, modification of transcript, and post-translation modification (Fig. 14). The 
Mcl-1 protein has a very short half-life (171,172), and as such many of the primary 
means of regulation are dependent on transcriptional mechanisms. Physiological 
mechanisms governing Mcl-1 transcription are highly dependent on cell type and 
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Figure 18. Mechanisms regulating Mcl-1. Mcl-1 is regulated in a context-dependent 
manner by transcriptional, post-transcriptional, and post-translation mechanisms. 
Extracellular ligands signal through multiple transduction pathways to positively 
influence Mcl-1 transcription in part through STAT3, PU.1, and Elk-1. Hypoxia also 
directly upregulates Mcl-1 transcription through HIF-1, whereas stress-induced 
upregulation of E2F1 directly represses Mcl-1 transcription (italics: negative regulation). 
Mcl-1 transcript may also be alternatively spliced to create a shorter form of Mcl-1 
termed Mcl-1S, which is proapoptotic in nature. Finally, Mcl-1 may be regulated post-
translationally through caspase cleavage, phosphorylation, or ubiquitination. 
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developmental state, and since much of the research on Mcl-1 has concentrated on 
hematopoietic tissues, many of the mechanisms regulating Mcl-1 transcription have been 
identified in that context. Transcription of Mcl-1 can be positively influenced by various 
extracellular stimuli including cytokines, growth factors, colony stimulating factors, and 
interferons (173,174). Depending on the stimuli, these signals are mediated by one or 
more transduction pathways including the JAK/STAT, MEK/ERK, p38/MAPK and 
PI3K/AKT signal transduction pathways (173,174). 
Transcription factors residing at the ends of signal transduction pathways that 
positively regulate Mcl-1 transcription work primarily through three response elements 
within the MCL-1 promoter. Induction of Mcl-1 transcription through the PI3K/AKT 
pathway is mediated through the cAMP response element-binding (CREB) transcription 
factor, which directly binds a cAMP response element (CRE)-2 upstream of the 
transcription start site (175). Activation via the JAK/STAT pathway is the result of STAT 
binding to a serum-inducible element (SIE) (176-178), and activation through 
p38/MAPK-mediated pathways results in Ets family member PU.1 also binding to the 
SIE element (179). Additionally, activation through MEK/ERK also functions through 
the SIE element as mediated by Ets member Elk-1 (180). In addition to transcriptional 
control mediated by signal transduction pathways, Mcl-1 is also induced in hypoxic 
conditions through during binding of HIF-1 to the promoter (181). As previously eluded 
to, many of the previously described mechanisms regulating Mcl-1 transcription have 
been identified in hematopoietic tissue development, and it is not clear what role these 
ligands and signal transduction pathways play in regulating Mcl-1 transciption in other 
tissues. 
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While mechanisms positively regulating Mcl-1 transcription in the context of 
development and maturation of hematopoietic tissues are well described, less is known 
about how Mcl-1 is transcriptionally regulated in other tissues and other contexts—
specifically how it is repressed during the induction of apoptosis. Given the lability of the 
Mcl-1 protein, it reasonable to hypothesize that transcriptional downregulation of Mcl-1 
is not due to direct repression, but rather from a lack of positive signaling. Previous 
studies from our lab, however, have identified the E2F1 transcription factor as directly 
binding to and repressing the MCL-1 promoter (122). Interestingly, this is independent of 
pRb family member binding, although the exact mechanism has not yet been determined. 
As described in the following section, Mcl-1 is thought to play a critical role in 
promoting the survival of malignant cells, and as such elucidating mechanisms regulating 
Mcl-1 transcription in this context is of great importance. 
In addition to transcriptional regulation, Mcl-1 is also subject to post-
transcriptional and post-translational modification. In some contexts, Mcl-1 undergoes 
alternative splicing to produce a shorter from of Mcl-1 (termed Mcl-1S) (182,183). This 
modification results in the loss of the TM domain as well as BH1-2 domains, giving way 
to an alternate Mcl-1 protein with a structure similar to that of the BH3-only subfamily 
members (182,183). Indeed, Mcl-1S does not bind to proapoptotic Bcl-2 family members 
but instead binds to antiapoptotic members, and its overexpression is sufficient to induce 
apoptosis (182,183). Mechanisms of post-translational modification include cleavage, 
phosphorylation, and ubquitination. During apoptosis, Mcl-1 is subject to caspase-
mediated cleavage at conserved aspartic acid residues (184,185), with one the resultant 
cleavage products being proapoptotic in nature in overexpression assays (184). In the 
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case of phosphorylation, Mcl-1 is phosphorylated through multiple mechanisms at two 
specific serine residues that can either positively or negatively influence Mcl-1 protein 
levels. Oxidative stress inactivates Mcl-1 via JNK-mediated phosphoryalation at serine-
121 and threonine Thr-163 (186), and Mcl-1 is also phosphorylated at Thr-163 via TPA 
by Erk-dependent mechanisms—leading to increased protein stability (187,188). There 
are purported to be other phosphorylation sites in Mcl-1, but they have yet to be 
characterized (188). Finally, Mcl-1 is subject to ubiquitination by Mule/ARF-BP1, which 
negatively regulates Mcl-1 protein by targeting it for proteasomal degradation (189). 
Taken together, Mcl-1 is subject to both positive and negative regulation at multiple 
levels through multiple mechanisms. 
 
Mcl-1 and human malignancy 
 
While in itself not a direct oncogene, as described in a previous section Mcl-1 
may behave as an oncogene when present in combination with other oncogenic mutations 
due to its potent ability to promote survival. This is partially exemplified by studies 
demonstrating correlations between Mcl-1 expression and disease outcomes. In chronic 
lymphocytic leukemia, a higher level of Mcl-1 expression correlates with failure to 
achieve complete remission, and in breast cancer Mcl-1 expression associates with poor 
prognosis (190,191). Additionally, Mcl-1 expression is associated with disease 
progression in melanoma, and is also a predictor of survival in gastric carcinoma 
(192,193). Experiments utilizing siRNA-mediated knockdown of Mcl-1 in cancerous 
cells has also pointed at the integral role Mcl-1 may play promoting malignant cell 
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viability. Indeed, antisense depletion of Mcl-1 in malignant cell can lead to decreased 
viability and the induction apoptosis—suggesting that interfering with Mcl-1 expression 
may prove to be a rational therapy for human malignancies (163-166). 
 
Summary and rationale 
 
Mcl-1 is an antiapoptotic Bcl-2 family member, and as such may act as a potent 
oncogene due to its ability to promote cell survival. Indeed, antisense depletion of Mcl-1 
can induce loss of viability and apoptosis in malignant cells—exemplifying the necessity 
of Mcl-1 expression to their survival (163-166). Since Mcl-1 is a labile protein, much of 
its regulation is thought to be dependent on transcriptional mechanisms. A publication 
from Moshynska et al. identified two novel sequence variants of the MCL-1 promoter 
within lymphocytes from chronic lymphocytic leukemia patients, but not within 
noncancerous tissue from the same individuals or in lymphocytes from 18 healthy control 
subjects (1). This result suggested that the variants—insertions of 6 or 18 nucleotides at 
position –188 relative to the transcription start site (194)—were CLL-related somatic 
oncogenic mutations. Moshynska et al. also determined that the 6- and 18-nucleotide 
insertions were associated with elevated Mcl-1 expression, and proposed that the variant 
promoters could be used as a prognostic marker. We independently identified and cloned 
the three observed sequence variants from cancer cell lines hereby referred to as the 
MCL-1 +0, +6 or +18 promoters. In contrast to Moshynska et al., we find the variant 
promoters to be identically present in both cancerous and adjacent noncancerous clinical 
lung samples, suggesting that the variants are germ-line encoded. We also find the three 
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variant promoters prevalent in genomic DNA derived from healthy control samples and 
present at frequencies similar to that observed in cancerous cell lines. Furthermore, 
activity analysis of the three variant promoters reveals the MCL-1 +6 and +18 promoters 
to be less active than the MCL-1 +0 promoter, both during normal cellular homeostasis 
and under conditions that actively induce MCL-1 transcription. Given our results, we 
conclude that the MCL-1 +6 and +18 promoters are likely benign polymorphisms and do 
no represent a reliable prognostic marker for CLL. 
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Experimental Procedures 
 
Promoter identification and screening 
 
Genomic DNA was extracted from cell lines as described (Sambrook J, Russell 
DW. Molecular Cloning: A Laboratory Manual. 3rd ed. New York: Cold Spring Harbor 
Laboratory Press; 2001, p. 8.46-8.53). Mcl-1 promoter sequence from cell lines 
representative of the three aberrances, namely H1299, K562, and T98G, was amplified 
from genomic DNA using a primer pair that spanned bases –223 to –246 (5'-AGG CCC 
GAG GTG CTC ATG GAA AGA-3') and +72 to +93 (5'-TTG AGG CCA AAC ATT 
GCC AGT CA-3') of what is referred to as the Mcl-1 +0 promoter. The resulting products 
were cloned into pCR2.1-TOPO using the TOPO TA Cloning Kit (Invitrogen) and the 
products sequenced by the Moffitt Molecular Biology Core. For larger scale screening 
purposes, a primer pair that spanned bases –110 to –129 (5'-AGC TTC CGG AGG GTT 
GCG CA-3') and –162 to –182 (5'-GGC ACT CAG AGC CTC CGA AGA-3') were used 
to amplify the Mcl-1 promoter with the resulting products resolved on a 6% 
polyacrylamide gel and visualized after exposure to ethidium bromide. 
 
 
 
76 
Cell lines 
 
Breast cancer cell lines screened consists of: MDA-MB-231, MDA-MB-361, 
MDA-MB-361, MDA-MB-435s, MDA-MB-453, MDA-MB-468, MCF7, SK-BR-3 and 
T47D. Lung cancer lines screened consist of: H322, H358, H324, H661, H522, H146, 
H209, H417, H82 and H211. 
 
Paired clinical lung samples 
 
All patient and control donors provided informed consent as approved by the 
Institutional Review Board. Lung tumor and corresponding normal lung tissue specimens 
were collected from patients undergoing routine thoracotomy for surgical resection of 
their malignancy. Resected specimens were briefly inspected by a surgical pathologist 
and then snap-frozen in liquid nitrogen. Frozen sections were microscopically viewed to 
assess the proportion of tumor cells, normal cells, and necrotic cells in tumor specimens 
to ensure absence of malignant cells in normal specimens. None of the patients had 
received radiation or chemotherapy prior to sample collection. 
 
Healthy control samples 
 
Peripheral blood mononuclear cells were collected from healthy normal 
volunteers. None of the volunteers had a known malignancy or illness. All were 
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Caucasian except for one Hispanic and one Asian volunteer. The ages ranged from 19 to 
62, and 34 of the volunteers were female and 25 were male. 
 
Luciferase assays 
 
The above described pCR2.1-TOPO Mcl-1 +0, +6, and +18 constructs employed 
for the initial screening were shuttled into the pGL3 (Invitrogen) luciferase vectors, and 
the sequences were verified via sequencing by the Moffitt Molecular Biology Core. 
Luciferase assays were conducted using the Dual-Luciferase Reporter Assay System 
(Promega) following the published protocol. NIH/3T3 and K562 cells were grown to 
~70% confluency in 60 mm2 plates, and K562s were transfected at a density of 1.5 × 106 
cells per 60 mm2 plate. Lipofectamine and PLUS reagent (Invitrogen) were used for 
transfections following the published protocol. All transfections were conducted in 
triplicate. DNA concentrations per transfection were as follows: 1 μg pGL3/derivative, 
0.1 μg pRLTK internal control plasmid, and 0.9 μg carrier DNA. Cells were washed once 
with phosphate-buffered saline (PBS) and given new media at 4 hours after transfection. 
At 24 hours, cells were either harvested for analysis or induced to differentiate with 100 
nM phorbol 12-myristae 13-acetate (PMA). PMA treated cells were collected for analysis 
at 12 hours post treatment. For analysis of activity, luciferase activity was normalized to 
the internal renilla activity. 
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Results 
 
Identification of two novel MCL-1 promoter variants 
 
An article entitled “Prognostic Significance of a Short Sequence Insertion in the 
MCL-1 Promoter in Chronic Lymphocytic Leukemia” identified two novel sequence 
variants of the Mcl-1 promoter within lymphocytes from chronic lymphocytic leukemia 
patients, but not within noncancerous tissue from the same individual or in lymphocytes 
from 18 healthy control subjects (1). This result suggested that the variants—insertions of 
6 and 18 nucleotides at position –188 relative to the transcription start site as mapped by 
akgul et al. (194)—were CLL-related somatic oncogenic mutations. Moshynska et al. 
also determined that the 6- and 18-nucleotide insertions were associated with higher Mcl-
1 mRNA and protein, and may therefore hold prognostic significance. 
 In the course of analyzing the E2F1-mediated transcriptional repression of Mcl-1, 
we independently identified and cloned the three observed sequence variants from three 
human cancer cell lines, H1299(MCL-1 +0/+0) lung cancer cells, K562(MCL-1 +6/+6) 
erythroleukemia cells, and T98G(MCL-1 +0/+18) glioblastoma cells, representing the MCL-1 
+0, +6, and +18 alleles, respectively. We next used polymerase chain reaction, followed 
by resolution of the PCR products on acrylamide gels, to determine MCL-1 promoter 
status in a large number of cell lines and solid tumors. The MCL-1 +6 and MCL-1 +18 
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promoters occurred with a relatively high frequency in genomic DNA derived from both 
breast and lung cancer cell lines, although the common MCL-1 +0 allele was the most 
prevalent (Table 1). 
 
The MCL-1 +6 and MCL-1 +18 promoter variants are not the result of somatic mutation 
 
We next wanted to determine if the variant promoters were somatic in origin. To 
address this issue, we analyzed the MCL-1 promoter status of genomic DNA derived 
from 15 sets of paired lung cancer and adjacent normal lung tissue from patients 
undergoing routine thoracotomy for surgical resection of their malignancy. All samples 
were provided in deidentified fashion, and all patients provided informed consent as 
approved by the Institutional Review Board. In all 15 samples, the MCL-1 promoter 
profile was identical in cancerous and normal tissue (Fig. 18). Given this observation, we 
conclude that the variant promoters are not somatic in origin and are germ-line encoded. 
 
The MCLl-1 +6 and MCL-1 +18 promoters are common polymorphisms 
 
While we established that the variant promoters were not the result of somatic 
mutation, we considered the possibility that the MCL-1 promoter variants may predispose 
to malignancy. To this end, we screened genomic DNA derived from 59 healthy 
individuals, all of whom provided informed consent, for the presence of the variant Mcl-1 
promoters. Nearly half of the total alleles had one or both insertions, and the insertions 
occurred at frequencies similar to that observed in cancer cell lines (Fig. 19). Thus, it  
Table 1. The allelic frequencies of the MCL-1 +0, MCL-1 +6, and MCL-1 +18 
promoters in breast and lung cancer cell lines. 
 
 
MCL-1 +0
MCL-1 +6
MCL-1 +18
Allele Breast Lines (N=16) Lung Lines (N=20)
9 (56%) 10 (50%)
3 (19%)
4 (25%)
3 (15%)
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Figure 19. The variant MCL-1 promoters are not the result of somatic mutation. (A) 
Representative samples of the MCL-1 promoter status in genomic DNA from paired lung 
tumor biopsy and adjacent normal tissue derived from patients undergoing routine 
thoracotomy as determined by resolving PCR products from the MCL-1 promoter on a 
polyacrylamide gel with subsequent visualization. (B) The resultant allelic frequencies of 
all paired samples examined. 
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Figure 20. The variant MCL-1 promoters are prevalent in genomic DNA derived 
from healthy controls. (A) Representative samples of the MCL-1 promoter status in 
genomic DNA from healthy donor peripheral blood mononuclear cells as determined by 
resolving PCR products from the MCL-1 promoter on a polyacrylamide gel with 
subsequent visualization. (B) The resultant allelic frequencies of all healthy control 
samples examined. 
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appears likely that the MCL-1 +6 and +18 promoter variants are likely common benign 
polymorphisms. 
 
The MCL-1 +6 and MCL-1 +18 promoters are less active than the common MCL-1 +0 
promoter 
 
Mcl-1 belongs to the Bcl-1 family of proteins and may be a potent oncogene due 
to its ability to block apoptosis. Although we found the MCL-1 +6 and +18 
polymorphisms to be quite common, we considered it possible that they could contribute 
to oncogenesis by rendering the promoter more active, thereby increasing the expression 
of MCL-1. To explore this possibility, we cloned the MCL-1 +0, +6 and +18 promoters 
into a pGL3 luciferase vector, transfected the constructs into multiple cell lines, and 
determined promoter activity. Surprisingly the variant promoters displayed decreased 
activity—both during normal cellular homeostasis and under conditions that actively 
induce Mcl-1 transcription (i.e., treatment with phorbol 12-myristate 13-acetate (PMA)), 
with the +18 promoter displaying approximately half the activity of the MCL-1 +0 
promoter (Fig. 20A, B and C). Taken together, we conclude that the MCL-1 +6 and +18 
variant promoters likely represent benign polymorphisms that probably do not represent a 
reliable prognostic marker. 
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Figure 21. The MCL-1 +6 and MCL-1 +18 promoters are less active than the MCL-
1 +0 promoter. (A) Luciferase constructs representing the three variant MCL-1 
promoters and a renilla control construct were cotransfected into NIH/3T3s with the 
MCL-1 promoter constructs assayed for activity relative to the renilla internal control 24 
hours post transfection. (B and C) Transfections conducted as in figure 20A, except 
MCF7 and K562 cells were treated in parallel plus or minus PMA to induce Mcl-1 
transcription. Cells were harvested after 12 hours of PMA treatment. 
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Discussion 
 
While there are significant disagreements between our data and that published by 
Moshynska et al. (1), there is agreement as to the existence, location, and composition of 
the MCL-1 +6 and +18 variant promoters. Beyond that however, there is little common 
ground. Moshynska et al. claim that to have specifically found the MCL-1 +6 and +18 
promoters only in genomic DNA derived from lymphocytes from CLL patients and not 
within cancerous tissue derived from the same individuals or in lymphocytes from 
healthy control subjects, suggesting that the variants are CLL-related oncogenic 
mutations. In contrast, we find the variant promoters identically present in paired samples 
of cancerous and adjacent noncancerous lung, and also find the promoters prevalent in 
genomic DNA derived from healthy volunteers (195). Similar studies investigating the 
variant MCL-1 promoters are in agreement with our results. Vargas et al. report the 
variant promoters present in 24 healthy control samples, and Iglesias-Serret et al. find the 
variant promoters present in lymphocytes from CLL patients as well as lymphocytes from 
10 control subjects and mouth epithelial cells from 10 additional healthy control subjects 
(196,197). Experiments by Dicker et al. find MCL-1 promoter status identical between 
that observed in lymphocytes from CLL patients and in genomic DNA derived from 
buccal swabs, and further find the MCL-1 +6 and +18 promoters common DNA samples 
from health control individuals (198). Coenen et al. have also reported similar results 
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(199). Given the bulk of evidence in support of our data, we confidently conclude that the 
variant MCL-1 promoters are not the result of a CLL-related oncogenic mutation and 
instead represent common benign polymorphisms. 
A second assertion from the Moshynska publication was that the presence of the 
MCL-1 +6 and +18 promoters correlated with increased expression of MCL-1 mRNA 
and protein (1). To investigate the effect of the MCL-1 +6 and +18 variants on promoter 
activity, we cloned the MCL-1 +0, +6, and +18 promoters into luciferase vectors and 
assayed them for activity in multiple cell lines and found the MCL-1 +6 and +18 
promoters to be less active than the common MCL-1 +0 promoter, both during normal 
cellular homeostasis and under conditions that actively induce Mcl-1 transcription (195). 
Unfortunately, most studies investigating the variant MCL-1 promoters did not conduct 
expression assays, however one study did compare MCL-1 promoter status to Mcl-1 
expression in CLL patients via microarray, but observed no correlation (198). It is 
possible that the reported positive correlation by Moshynska et al. is real, however our 
promoter activity assay would argue otherwise. Therefore, we assert that under our 
experimental conditions, the variant MCL-1 +6 and +18 promoters are less active than 
the common MCL-1 +0 promoter. 
Another major finding from the Moshynska et al. publication is that the MCL-1 
+6 and +18 variant promoters positively correlate with risk of dying and decreased 
disease-free survival in CLL patients (1). Since our studies did not examine an 
association with CLL, we do not definitively disagree with this statement. However, the 
finding by ourselves and others that the MCL-1 +6 and +8 promoters are actually 
common polymorphisms with no discernable correlation to malignancy highlights a 
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fundamental flaw in either the screening technique, data reporting, or both employed by 
Moshynska et al. This in itself is sufficient to be skeptical of any analyses and 
conclusions inferred from their data, yet other studies conducting similar sets of 
experiments have thoroughly demonstrated that the MCL-1 +6 or +18 promoters do not 
correlate with disease outcomes in either CLL or acute lymphoblastic leukemia (ALL) 
(198-201). Thus, whether an error in the screening technique or an error in reporting, it is 
clear that the MCL-1 +6 and +18 promoters hold no prognostic significance to CLL.  
It is unclear why there are so many discrepancies between the work of ourselves 
and others and that presented by Moshynska et al. As previously mentioned, the gross 
amounts of errors are likely the result of a flawed screening technique, flawed data 
reporting, or both. In our experiments, we utilized a PCR-based screening technique that 
allowed for a clear distinction of both MCL-1 promoter alleles of a sample by virtue of 
differences in migration within the different sized PCR products. However, the technique 
employed by Moshynska et al. consisted of direct sequencing of PCR products, which in 
theory should be a reliable technique. And, given the complete absence of the MCL-1 +6 
and MCL-1 +18 promoters in every sample they examined except CLL cells, it is 
unlikely that this scenario could occur completely by chance. Taken together, we 
conclude that the MCL-1 +6 and +18 promoters are common benign polymorphisms that 
likely hold no prognostic value for CLL, that the MCL-1 +6 and +18 promoters are less 
active than the MCL-1 +0 promoter, and that the discrepancies found within the 
Moshynska publication are likely the result of an error in data reporting. 
87 
 
 
 
LIST OF REFERENCES 
 
1. Moshynska, O., Sankaran, K., Pahwa, P., and Saxena, A. (2004) J Natl Cancer 
Inst 96(9), 673-682 
2. Bracken, A. P., Ciro, M., Cocito, A., and Helin, K. (2004) Trends Biochem Sci 
29(8), 409-417 
3. DeGregori, J., and Johnson, D. G. (2006) Curr Mol Med 6(7), 739-748 
4. Johnson, D. G., and Degregori, J. (2006) Curr Mol Med 6(7), 731-738 
5. Cam, H., and Dynlacht, B. D. (2003) Cancer Cell 3(4), 311-316 
6. Harbour, J. W., and Dean, D. C. (2000) Genes Dev 14(19), 2393-2409 
7. Nevins, J. R. (2001) Hum Mol Genet 10(7), 699-703 
8. DeGregori, J. (2002) Biochim Biophys Acta 1602(2), 131-150 
9. Dimova, D. K., and Dyson, N. J. (2005) Oncogene 24(17), 2810-2826 
10. Dyson, N. (1998) Genes Dev 12(15), 2245-2262 
11. Trimarchi, J. M., and Lees, J. A. (2002) Nat Rev Mol Cell Biol 3(1), 11-20 
12. Wang, S., Ghosh, R. N., and Chellappan, S. P. (1998) Mol Cell Biol 18(12), 7487-
7498 
13. Kato, J., Matsushime, H., Hiebert, S. W., Ewen, M. E., and Sherr, C. J. (1993) 
Genes Dev 7(3), 331-342 
14. Meyerson, M., and Harlow, E. (1994) Mol Cell Biol 14(3), 2077-2086 
15. Johnson, D. G., Ohtani, K., and Nevins, J. R. (1994) Genes Dev 8(13), 1514-1525 
88 
16. Hsiao, K. M., McMahon, S. L., and Farnham, P. J. (1994) Genes Dev 8(13), 1526-
1537 
17. Neuman, E., Flemington, E. K., Sellers, W. R., and Kaelin, W. G., Jr. (1994) Mol 
Cell Biol 14(10), 6607-6615 
18. Ohtani, K., DeGregori, J., and Nevins, J. R. (1995) Proc Natl Acad Sci U S A 
92(26), 12146-12150 
19. Dynlacht, B. D., Flores, O., Lees, J. A., and Harlow, E. (1994) Genes Dev 8(15), 
1772-1786 
20. DeGregori, J., Kowalik, T., and Nevins, J. R. (1995) Molecular and cellular 
biology 15(8), 4215-4224 
21. Zhang, L., and Wang, C. (2006) Oncogene 25(18), 2615-2627 
22. Xu, M., Sheppard, K. A., Peng, C. Y., Yee, A. S., and Piwnica-Worms, H. (1994) 
Mol Cell Biol 14(12), 8420-8431 
23. Marti, A., Wirbelauer, C., Scheffner, M., and Krek, W. (1999) Nat Cell Biol 1(1), 
14-19 
24. Friend, S. H., Bernards, R., Rogelj, S., Weinberg, R. A., Rapaport, J. M., Albert, 
D. M., and Dryja, T. P. (1986) Nature 323(6089), 643-646 
25. Knudson, A. G., Jr. (1971) Proc Natl Acad Sci U S A 68(4), 820-823 
26. Serrano, M., Hannon, G. J., and Beach, D. (1993) Nature 366(6456), 704-707 
27. Veltman, J. A., Fridlyand, J., Pejavar, S., Olshen, A. B., Korkola, J. E., DeVries, 
S., Carroll, P., Kuo, W. L., Pinkel, D., Albertson, D., Cordon-Cardo, C., Jain, A. 
N., and Waldman, F. M. (2003) Cancer Res 63(11), 2872-2880 
89 
28. Orlic, M., Spencer, C. E., Wang, L., and Gallie, B. L. (2006) Genes Chromosomes 
Cancer 45(1), 72-82 
29. Oeggerli, M., Tomovska, S., Schraml, P., Calvano-Forte, D., Schafroth, S., 
Simon, R., Gasser, T., Mihatsch, M. J., and Sauter, G. (2004) Oncogene 23(33), 
5616-5623 
30. Foster, C. S., Falconer, A., Dodson, A. R., Norman, A. R., Dennis, N., Fletcher, 
A., Southgate, C., Dowe, A., Dearnaley, D., Jhavar, S., Eeles, R., Feber, A., and 
Cooper, C. S. (2004) Oncogene 23(35), 5871-5879 
31. Grasemann, C., Gratias, S., Stephan, H., Schuler, A., Schramm, A., Klein-Hitpass, 
L., Rieder, H., Schneider, S., Kappes, F., Eggert, A., and Lohmann, D. R. (2005) 
Oncogene 24(42), 6441-6449 
32. Saito, M., Helin, K., Valentine, M. B., Griffith, B. B., Willman, C. L., Harlow, E., 
and Look, A. T. (1995) Genomics 25(1), 130-138 
33. Fujita, Y., Sakakura, C., Shimomura, K., Nakanishi, M., Yasuoka, R., Aragane, 
H., Hagiwara, A., Abe, T., Inazawa, J., and Yamagishi, H. (2003) 
Hepatogastroenterology 50(54), 1857-1863 
34. Brookman-Amissah, N., Duchesnes, C., Williamson, M. P., Wang, Q., Ahmed, 
A., Feneley, M. R., Mackay, A., Freeman, A., Fenwick, K., Iravani, M., Weber, 
B., Ashworth, A., and Masters, J. R. (2005) Prostate cancer and prostatic 
diseases 8(4), 335-343 
35. Watanabe, T., Imoto, I., Katahira, T., Hirasawa, A., Ishiwata, I., Emi, M., 
Takayama, M., Sato, A., and Inazawa, J. (2002) Jpn J Cancer Res 93(10), 1114-
1122 
90 
36. Postma, C., Hermsen, M. A., Coffa, J., Baak, J. P., Mueller, J. D., Mueller, E., 
Bethke, B., Schouten, J. P., Stolte, M., and Meijer, G. A. (2005) J Pathol 205(4), 
514-521 
37. Suzuki, T., Yasui, W., Yokozaki, H., Naka, K., Ishikawa, T., and Tahara, E. 
(1999) Int J Cancer 81(4), 535-538 
38. Lee, T. A., and Farnham, P. J. (2000) Oncogene 19(18), 2257-2268 
39. Melillo, R. M., Helin, K., Lowy, D. R., and Schiller, J. T. (1994) Mol Cell Biol 
14(12), 8241-8249 
40. Pierce, A. M., Schneider-Broussard, R., Gimenez-Conti, I. B., Russell, J. L., 
Conti, C. J., and Johnson, D. G. (1999) Mol Cell Biol 19(9), 6408-6414 
41. Russell, J. L., Weaks, R. L., Berton, T. R., and Johnson, D. G. (2006) Oncogene 
25(6), 867-876 
42. Frame, F. M., Rogoff, H. A., Pickering, M. T., Cress, W. D., and Kowalik, T. F. 
(2006) Oncogene 25(23), 3258-3266 
43. Dimri, G. P., Itahana, K., Acosta, M., and Campisi, J. (2000) Mol Cell Biol 20(1), 
273-285 
44. Lomazzi, M., Moroni, M. C., Jensen, M. R., Frittoli, E., and Helin, K. (2002) Nat 
Genet 31(2), 190-194 
45. Lazzerini Denchi, E., Attwooll, C., Pasini, D., and Helin, K. (2005) Mol Cell Biol 
25(7), 2660-2672 
46. Yee, A. S., Reichel, R., Kovesdi, I., and Nevins, J. R. (1987) Embo J 6(7), 2061-
2068 
91 
47. Ivey-Hoyle, M., Conroy, R., Huber, H. E., Goodhart, P. J., Oliff, A., and 
Heimbrook, D. C. (1993) Mol Cell Biol 13(12), 7802-7812 
48. Lees, J. A., Saito, M., Vidal, M., Valentine, M., Look, T., Harlow, E., Dyson, N., 
and Helin, K. (1993) Mol Cell Biol 13(12), 7813-7825 
49. Leone, G., Nuckolls, F., Ishida, S., Adams, M., Sears, R., Jakoi, L., Miron, A., 
and Nevins, J. R. (2000) Mol Cell Biol 20(10), 3626-3632 
50. He, Y., Armanious, M. K., Thomas, M. J., and Cress, W. D. (2000) Oncogene 
19(30), 3422-3433 
51. Ginsberg, D., Vairo, G., Chittenden, T., Xiao, Z. X., Xu, G., Wydner, K. L., 
DeCaprio, J. A., Lawrence, J. B., and Livingston, D. M. (1994) Genes Dev 8(22), 
2665-2679 
52. Beijersbergen, R. L., Kerkhoven, R. M., Zhu, L., Carlee, L., Voorhoeve, P. M., 
and Bernards, R. (1994) Genes Dev 8(22), 2680-2690 
53. Buck, V., Allen, K. E., Sorensen, T., Bybee, A., Hijmans, E. M., Voorhoeve, P. 
M., Bernards, R., and La Thangue, N. B. (1995) Oncogene 11(1), 31-38 
54. Itoh, A., Levinson, S. F., Morita, T., Kourembanas, S., Brody, J. S., and Mitsialis, 
S. A. (1995) Cell Mol Biol Res 41(3), 147-154 
55. Trimarchi, J. M., Fairchild, B., Verona, R., Moberg, K., Andon, N., and Lees, J. 
A. (1998) Proc Natl Acad Sci U S A 95(6), 2850-2855 
56. Cartwright, P., Muller, H., Wagener, C., Holm, K., and Helin, K. (1998) 
Oncogene 17(5), 611-623 
57. Gaubatz, S., Wood, J. G., and Livingston, D. M. (1998) Proc Natl Acad Sci U S A 
95(16), 9190-9195 
92 
58. de Bruin, A., Maiti, B., Jakoi, L., Timmers, C., Buerki, R., and Leone, G. (2003) J 
Biol Chem 278(43), 42041-42049 
59. Di Stefano, L., Jensen, M. R., and Helin, K. (2003) Embo J 22(23), 6289-6298 
60. Logan, N., Delavaine, L., Graham, A., Reilly, C., Wilson, J., Brummelkamp, T. 
R., Hijmans, E. M., Bernards, R., and La Thangue, N. B. (2004) Oncogene 
23(30), 5138-5150 
61. Maiti, B., Li, J., de Bruin, A., Gordon, F., Timmers, C., Opavsky, R., Patil, K., 
Tuttle, J., Cleghorn, W., and Leone, G. (2005) J Biol Chem 280(18), 18211-18220 
62. Christensen, J., Cloos, P., Toftegaard, U., Klinkenberg, D., Bracken, A. P., Trinh, 
E., Heeran, M., Di Stefano, L., and Helin, K. (2005) Nucleic Acids Res 33(17), 
5458-5470 
63. Sears, R., Ohtani, K., and Nevins, J. R. (1997) Mol Cell Biol 17(9), 5227-5235 
64. Trimarchi, J. M., Fairchild, B., Wen, J., and Lees, J. A. (2001) Proc Natl Acad Sci 
U S A 98(4), 1519-1524 
65. Logan, N., Graham, A., Zhao, X., Fisher, R., Maiti, B., Leone, G., and La 
Thangue, N. B. (2005) Oncogene 24(31), 5000-5004 
66. Johnson, D. G., Schwarz, J. K., Cress, W. D., and Nevins, J. R. (1993) Nature 
365(6444), 349-352 
67. Qin, X. Q., Livingston, D. M., Kaelin, W. G., Jr., and Adams, P. D. (1994) Proc 
Natl Acad Sci U S A 91(23), 10918-10922 
68. DeGregori, J., Leone, G., Miron, A., Jakoi, L., and Nevins, J. R. (1997) Proc Natl 
Acad Sci U S A 94(14), 7245-7250 
93 
69. Lukas, J., Petersen, B. O., Holm, K., Bartek, J., and Helin, K. (1996) Mol Cell 
Biol 16(3), 1047-1057 
70. DeGregori, J., Leone, G., Ohtani, K., Miron, A., and Nevins, J. R. (1995) Genes 
Dev 9(23), 2873-2887 
71. Schwarz, J. K., Bassing, C. H., Kovesdi, I., Datto, M. B., Blazing, M., George, S., 
Wang, X. F., and Nevins, J. R. (1995) Proc Natl Acad Sci U S A 92(2), 483-487 
72. Mann, D. J., and Jones, N. C. (1996) Curr Biol 6(4), 474-483 
73. Johnson, D. G., Cress, W. D., Jakoi, L., and Nevins, J. R. (1994) Proc Natl Acad 
Sci U S A 91(26), 12823-12827 
74. Shan, B., and Lee, W. H. (1994) Mol Cell Biol 14(12), 8166-8173 
75. Singh, P., Wong, S. H., and Hong, W. (1994) Embo J 13(14), 3329-3338 
76. Xu, G., Livingston, D. M., and Krek, W. (1995) Proc Natl Acad Sci U S A 92(5), 
1357-1361 
77. Chen, Q., Liang, D., Yang, T., Leone, G., and Overbeek, P. A. (2004) Dev 
Neurosci 26(5-6), 435-445 
78. Chen, Q., Hung, F. C., Fromm, L., and Overbeek, P. A. (2000) Invest Ophthalmol 
Vis Sci 41(13), 4223-4231 
79. Guy, C. T., Zhou, W., Kaufman, S., and Robinson, M. O. (1996) Mol Cell Biol 
16(2), 685-693 
80. Pierce, A. M., Fisher, S. M., Conti, C. J., and Johnson, D. G. (1998) Oncogene 
16(10), 1267-1276 
81. Paulson, Q. X., McArthur, M. J., and Johnson, D. G. (2006) Cell Cycle 5(2), 184-
190 
94 
82. Scheijen, B., Bronk, M., van der Meer, T., De Jong, D., and Bernards, R. (2004) J 
Biol Chem 279(11), 10476-10483 
83. Conner, E. A., Lemmer, E. R., Omori, M., Wirth, P. J., Factor, V. M., and 
Thorgeirsson, S. S. (2000) Oncogene 19(44), 5054-5062 
84. Agger, K., Santoni-Rugiu, E., Holmberg, C., Karlstrom, O., and Helin, K. (2005) 
Oncogene 24(5), 780-789 
85. Pierce, A. M., Gimenez-Conti, I. B., Schneider-Broussard, R., Martinez, L. A., 
Conti, C. J., and Johnson, D. G. (1998) Proc Natl Acad Sci U S A 95(15), 8858-
8863 
86. Vigo, E., Muller, H., Prosperini, E., Hateboer, G., Cartwright, P., Moroni, M. C., 
and Helin, K. (1999) Mol Cell Biol 19(9), 6379-6395 
87. Kowalik, T. F., DeGregori, J., Leone, G., Jakoi, L., and Nevins, J. R. (1998) Cell 
Growth Differ 9(2), 113-118 
88. Wu, X., and Levine, A. J. (1994) Proc Natl Acad Sci U S A 91(9), 3602-3606 
89. Kowalik, T. F., DeGregori, J., Schwarz, J. K., and Nevins, J. R. (1995) Journal of 
virology 69(4), 2491-2500 
90. Holmberg, C., Helin, K., Sehested, M., and Karlstrom, O. (1998) Oncogene 17(2), 
143-155 
91. Lazzerini Denchi, E., and Helin, K. (2005) EMBO Rep 6(7), 661-668 
92. Berton, T. R., Mitchell, D. L., Guo, R., and Johnson, D. G. (2005) Oncogene 
24(15), 2449-2460 
95 
93. Wikonkal, N. M., Remenyik, E., Knezevic, D., Zhang, W., Liu, M., Zhao, H., 
Berton, T. R., Johnson, D. G., and Brash, D. E. (2003) Nat Cell Biol 5(7), 655-
660 
94. Yamasaki, L., Jacks, T., Bronson, R., Goillot, E., Harlow, E., and Dyson, N. J. 
(1996) Cell 85(4), 537-548 
95. Cloud, J. E., Rogers, C., Reza, T. L., Ziebold, U., Stone, J. R., Picard, M. H., 
Caron, A. M., Bronson, R. T., and Lees, J. A. (2002) Mol Cell Biol 22(8), 2663-
2672 
96. Zhu, J. W., Field, S. J., Gore, L., Thompson, M., Yang, H., Fujiwara, Y., Cardiff, 
R. D., Greenberg, M., Orkin, S. H., and DeGregori, J. (2001) Mol Cell Biol 
21(24), 8547-8564 
97. Murga, M., Fernandez-Capetillo, O., Field, S. J., Moreno, B., Borlado, L. R., 
Fujiwara, Y., Balomenos, D., Vicario, A., Carrera, A. C., Orkin, S. H., Greenberg, 
M. E., and Zubiaga, A. M. (2001) Immunity 15(6), 959-970 
98. DeRyckere, D., and DeGregori, J. (2005) J Immunol 175(2), 647-655 
99. Li, F. X., Zhu, J. W., Hogan, C. J., and DeGregori, J. (2003) Mol Cell Biol 23(10), 
3607-3622 
100. Stevaux, O., and Dyson, N. J. (2002) Curr Opin Cell Biol 14(6), 684-691 
101. Ishida, S., Huang, E., Zuzan, H., Spang, R., Leone, G., West, M., and Nevins, J. 
R. (2001) Mol Cell Biol 21(14), 4684-4699 
102. Ren, B., Cam, H., Takahashi, Y., Volkert, T., Terragni, J., Young, R. A., and 
Dynlacht, B. D. (2002) Genes Dev 16(2), 245-256 
96 
103. Weinmann, A. S., Yan, P. S., Oberley, M. J., Huang, T. H., and Farnham, P. J. 
(2002) Genes Dev 16(2), 235-244 
104. Zhu, W., Giangrande, P. H., and Nevins, J. R. (2004) Embo J 23(23), 4615-4626 
105. Hernando, E., Nahle, Z., Juan, G., Diaz-Rodriguez, E., Alaminos, M., Hemann, 
M., Michel, L., Mittal, V., Gerald, W., Benezra, R., Lowe, S. W., and Cordon-
Cardo, C. (2004) Nature 430(7001), 797-802 
106. Hiebert, S. W., Packham, G., Strom, D. K., Haffner, R., Oren, M., Zambetti, G., 
and Cleveland, J. L. (1995) Mol Cell Biol 15(12), 6864-6874 
107. Bates, S., Phillips, A. C., Clark, P. A., Stott, F., Peters, G., Ludwig, R. L., and 
Vousden, K. H. (1998) Nature 395(6698), 124-125 
108. Kamijo, T., Weber, J. D., Zambetti, G., Zindy, F., Roussel, M. F., and Sherr, C. J. 
(1998) Proc Natl Acad Sci U S A 95(14), 8292-8297 
109. Zhang, Y., Xiong, Y., and Yarbrough, W. G. (1998) Cell 92(6), 725-734 
110. Haupt, Y., Maya, R., Kazaz, A., and Oren, M. (1997) Nature 387(6630), 296-299 
111. Kubbutat, M. H., Jones, S. N., and Vousden, K. H. (1997) Nature 387(6630), 299-
303 
112. Canman, C. E., Lim, D. S., Cimprich, K. A., Taya, Y., Tamai, K., Sakaguchi, K., 
Appella, E., Kastan, M. B., and Siliciano, J. D. (1998) Science 281(5383), 1677-
1679 
113. Banin, S., Moyal, L., Shieh, S., Taya, Y., Anderson, C. W., Chessa, L., 
Smorodinsky, N. I., Prives, C., Reiss, Y., Shiloh, Y., and Ziv, Y. (1998) Science 
281(5383), 1674-1677 
97 
114. Irwin, M., Marin, M. C., Phillips, A. C., Seelan, R. S., Smith, D. I., Liu, W., 
Flores, E. R., Tsai, K. Y., Jacks, T., Vousden, K. H., and Kaelin, W. G., Jr. (2000) 
Nature 407(6804), 645-648 
115. Stiewe, T., and Putzer, B. M. (2000) Nat Genet 26(4), 464-469 
116. Hershko, T., Chaussepied, M., Oren, M., and Ginsberg, D. (2005) Cell Death 
Differ 12(4), 377-383 
117. Real, P. J., Sanz, C., Gutierrez, O., Pipaon, C., Zubiaga, A. M., and Fernandez-
Luna, J. L. (2006) FEBS Lett 580(25), 5905-5909 
118. Rodriguez, J. M., Glozak, M. A., Ma, Y., and Cress, W. D. (2006) J Biol Chem 
281(32), 22729-22735 
119. Moroni, M. C., Hickman, E. S., Lazzerini Denchi, E., Caprara, G., Colli, E., 
Cecconi, F., Muller, H., and Helin, K. (2001) Nat Cell Biol 3(6), 552-558 
120. Xie, W., Jiang, P., Miao, L., Zhao, Y., Zhimin, Z., Qing, L., Zhu, W. G., and Wu, 
M. (2006) Nucleic Acids Res 34(7), 2046-2055 
121. Nahle, Z., Polakoff, J., Davuluri, R. V., McCurrach, M. E., Jacobson, M. D., 
Narita, M., Zhang, M. Q., Lazebnik, Y., Bar-Sagi, D., and Lowe, S. W. (2002) 
Nat Cell Biol 4(11), 859-864 
122. Croxton, R., Ma, Y., Song, L., Haura, E. B., and Cress, W. D. (2002) Oncogene 
21(9), 1359-1369 
123. Crowe, D. L., Nguyen, D. C., Tsang, K. J., and Kyo, S. (2001) Nucleic Acids Res 
29(13), 2789-2794 
124. Rothe, M., Sarma, V., Dixit, V. M., and Goeddel, D. V. (1995) Science 
269(5229), 1424-1427 
98 
125. Ma, Y., and Cress, W. D. (2007) Oncogene 26(24), 3532-3540 
126. Wang, C., Hou, X., Mohapatra, S., Ma, Y., Cress, W. D., Pledger, W. J., and 
Chen, J. (2005) The Journal of biological chemistry 280(13), 12339-12343 
127. Radhakrishnan, S. K., Feliciano, C. S., Najmabadi, F., Haegebarth, A., Kandel, E. 
S., Tyner, A. L., and Gartel, A. L. (2004) Oncogene 23(23), 4173-4176 
128. Stevens, C., and La Thangue, N. B. (2004) DNA Repair (Amst) 3(8-9), 1071-1079 
129. Ramos, S., Khademi, F., Somesh, B. P., and Rivero, F. (2002) Gene 298(2), 147-
157 
130. Lundgren, R., Mandahl, N., Heim, S., Limon, J., Henrikson, H., and Mitelman, F. 
(1992) Genes Chromosomes Cancer 4(1), 16-24 
131. Emi, M., Fujiwara, Y., Nakajima, T., Tsuchiya, E., Tsuda, H., Hirohashi, S., 
Maeda, Y., Tsuruta, K., Miyaki, M., and Nakamura, Y. (1992) Cancer Res 
52(19), 5368-5372 
132. Bova, G. S., Carter, B. S., Bussemakers, M. J., Emi, M., Fujiwara, Y., Kyprianou, 
N., Jacobs, S. C., Robinson, J. C., Epstein, J. I., Walsh, P. C., and et al. (1993) 
Cancer Res 53(17), 3869-3873 
133. Fujiwara, Y., Emi, M., Ohata, H., Kato, Y., Nakajima, T., Mori, T., and 
Nakamura, Y. (1993) Cancer Res 53(5), 1172-1174 
134. Sunwoo, J. B., Holt, M. S., Radford, D. M., Deeker, C., and Scholnick, S. B. 
(1996) Genes Chromosomes Cancer 16(3), 164-169 
135. Brown, M. R., Chuaqui, R., Vocke, C. D., Berchuck, A., Middleton, L. P., 
Emmert-Buck, M. R., and Kohn, E. C. (1999) Gynecol Oncol 74(1), 98-102 
99 
136. Wistuba, II, Behrens, C., Virmani, A. K., Milchgrub, S., Syed, S., Lam, S., 
Mackay, B., Minna, J. D., and Gazdar, A. F. (1999) Cancer Res 59(8), 1973-1979 
137. Rivero, F., Dislich, H., Glockner, G., and Noegel, A. A. (2001) Nucleic Acids Res 
29(5), 1068-1079 
138. Chang, F. K., Sato, N., Kobayashi-Simorowski, N., Yoshihara, T., Meth, J. L., 
and Hamaguchi, M. (2006) J Mol Biol 364(3), 302-308 
139. Collins, T., Stone, J. R., and Williams, A. J. (2001) Mol Cell Biol 21(11), 3609-
3615 
140. Furukawa, M., He, Y. J., Borchers, C., and Xiong, Y. (2003) Nat Cell Biol 5(11), 
1001-1007 
141. Geyer, R., Wee, S., Anderson, S., Yates, J., and Wolf, D. A. (2003) Mol Cell 
12(3), 783-790 
142. Pintard, L., Willis, J. H., Willems, A., Johnson, J. L., Srayko, M., Kurz, T., 
Glaser, S., Mains, P. E., Tyers, M., Bowerman, B., and Peter, M. (2003) Nature 
425(6955), 311-316 
143. Xu, L., Wei, Y., Reboul, J., Vaglio, P., Shin, T. H., Vidal, M., Elledge, S. J., and 
Harper, J. W. (2003) Nature 425(6955), 316-321 
144. Wilkins, A., Ping, Q., and Carpenter, C. L. (2004) Genes Dev 18(8), 856-861 
145. St-Pierre, B., Jiang, Z., Egan, S. E., and Zacksenhaus, E. (2004) Gene Expr 
Patterns 5(2), 245-251 
146. Hamaguchi, M., Meth, J. L., von Klitzing, C., Wei, W., Esposito, D., Rodgers, L., 
Walsh, T., Welcsh, P., King, M. C., and Wigler, M. H. (2002) Proc Natl Acad Sci 
U S A 99(21), 13647-13652 
100 
147. Yoshihara, T., Collado, D., and Hamaguchi, M. (2007) Biochem Biophys Res 
Commun 358(4), 1076-1079 
148. Siripurapu, V., Meth, J., Kobayashi, N., and Hamaguchi, M. (2005) J Mol Biol 
346(1), 83-89 
149. Wang, C., Chen, L., Hou, X., Li, Z., Kabra, N., Ma, Y., Nemoto, S., Finkel, T., 
Gu, W., Cress, W. D., and Chen, J. (2006) Nature cell biology 8(9), 1025-1031 
150. Ma, Y., Cress, W. D., and Haura, E. B. (2003) Molecular cancer therapeutics 
2(1), 73-81 
151. Kalejta, R. F., Shenk, T., and Beavis, A. J. (1997) Cytometry 29(4), 286-291 
152. Cory, S., Huang, D. C., and Adams, J. M. (2003) Oncogene 22(53), 8590-8607 
153. Adams, J. M., and Cory, S. (2007) Oncogene 26(9), 1324-1337 
154. Zou, H., Henzel, W. J., Liu, X., Lutschg, A., and Wang, X. (1997) Cell 90(3), 
405-413 
155. Li, P., Nijhawan, D., Budihardjo, I., Srinivasula, S. M., Ahmad, M., Alnemri, E. 
S., and Wang, X. (1997) Cell 91(4), 479-489 
156. Wei, M. C., Zong, W. X., Cheng, E. H., Lindsten, T., Panoutsakopoulou, V., 
Ross, A. J., Roth, K. A., MacGregor, G. R., Thompson, C. B., and Korsmeyer, S. 
J. (2001) Science 292(5517), 727-730 
157. Reynolds, J. E., Li, J., Craig, R. W., and Eastman, A. (1996) Exp Cell Res 225(2), 
430-436 
158. Reynolds, J. E., Yang, T., Qian, L., Jenkinson, J. D., Zhou, P., Eastman, A., and 
Craig, R. W. (1994) Cancer Res 54(24), 6348-6352 
101 
159. Zhou, P., Qian, L., Kozopas, K. M., and Craig, R. W. (1997) Blood 89(2), 630-
643 
160. Zhou, P., Levy, N. B., Xie, H., Qian, L., Lee, C. Y., Gascoyne, R. D., and Craig, 
R. W. (2001) Blood 97(12), 3902-3909 
161. Zhou, P., Qian, L., Bieszczad, C. K., Noelle, R., Binder, M., Levy, N. B., and 
Craig, R. W. (1998) Blood 92(9), 3226-3239 
162. Matsushita, K., Okita, H., Suzuki, A., Shimoda, K., Fukuma, M., Yamada, T., 
Urano, F., Honda, T., Sano, M., Iwanaga, S., Ogawa, S., Hata, J., and Umezawa, 
A. (2003) Mol Cell Endocrinol 203(1-2), 105-116 
163. Moulding, D. A., Giles, R. V., Spiller, D. G., White, M. R., Tidd, D. M., and 
Edwards, S. W. (2000) Blood 96(5), 1756-1763 
164. Zhang, B., Gojo, I., and Fenton, R. G. (2002) Blood 99(6), 1885-1893 
165. Derenne, S., Monia, B., Dean, N. M., Taylor, J. K., Rapp, M. J., Harousseau, J. 
L., Bataille, R., and Amiot, M. (2002) Blood 100(1), 194-199 
166. Leuenroth, S. J., Grutkoski, P. S., Ayala, A., and Simms, H. H. (2000) J Leukoc 
Biol 68(1), 158-166 
167. Rinkenberger, J. L., Horning, S., Klocke, B., Roth, K., and Korsmeyer, S. J. 
(2000) Genes Dev 14(1), 23-27 
168. Opferman, J. T., Letai, A., Beard, C., Sorcinelli, M. D., Ong, C. C., and 
Korsmeyer, S. J. (2003) Nature 426(6967), 671-676 
169. Opferman, J. T., Iwasaki, H., Ong, C. C., Suh, H., Mizuno, S., Akashi, K., and 
Korsmeyer, S. J. (2005) Science 307(5712), 1101-1104 
170. Dzhagalov, I., St John, A., and He, Y. W. (2007) Blood 109(4), 1620-1626 
102 
171. Chao, J. R., Wang, J. M., Lee, S. F., Peng, H. W., Lin, Y. H., Chou, C. H., Li, J. 
C., Huang, H. M., Chou, C. K., Kuo, M. L., Yen, J. J., and Yang-Yen, H. F. 
(1998) Mol Cell Biol 18(8), 4883-4898 
172. Nijhawan, D., Fang, M., Traer, E., Zhong, Q., Gao, W., Du, F., and Wang, X. 
(2003) Genes Dev 17(12), 1475-1486 
173. Craig, R. W. (2002) Leukemia 16(4), 444-454 
174. Le Gouill, S., Podar, K., Harousseau, J. L., and Anderson, K. C. (2004) Cell Cycle 
3(10), 1259-1262 
175. Wang, J. M., Chao, J. R., Chen, W., Kuo, M. L., Yen, J. J., and Yang-Yen, H. F. 
(1999) Mol Cell Biol 19(9), 6195-6206 
176. Puthier, D., Bataille, R., and Amiot, M. (1999) Eur J Immunol 29(12), 3945-3950 
177. Epling-Burnette, P. K., Liu, J. H., Catlett-Falcone, R., Turkson, J., Oshiro, M., 
Kothapalli, R., Li, Y., Wang, J. M., Yang-Yen, H. F., Karras, J., Jove, R., and 
Loughran, T. P., Jr. (2001) J Clin Invest 107(3), 351-362 
178. Epling-Burnette, P. K., Zhong, B., Bai, F., Jiang, K., Bailey, R. D., Garcia, R., 
Jove, R., Djeu, J. Y., Loughran, T. P., Jr., and Wei, S. (2001) J Immunol 166(12), 
7486-7495 
179. Wang, J. M., Lai, M. Z., and Yang-Yen, H. F. (2003) Mol Cell Biol 23(6), 1896-
1909 
180. Townsend, K. J., Zhou, P., Qian, L., Bieszczad, C. K., Lowrey, C. H., Yen, A., 
and Craig, R. W. (1999) J Biol Chem 274(3), 1801-1813 
181. Piret, J. P., Minet, E., Cosse, J. P., Ninane, N., Debacq, C., Raes, M., and 
Michiels, C. (2005) J Biol Chem 280(10), 9336-9344 
103 
182. Bae, J., Leo, C. P., Hsu, S. Y., and Hsueh, A. J. (2000) J Biol Chem 275(33), 
25255-25261 
183. Bingle, C. D., Craig, R. W., Swales, B. M., Singleton, V., Zhou, P., and Whyte, 
M. K. (2000) J Biol Chem 275(29), 22136-22146 
184. Michels, J., O'Neill, J. W., Dallman, C. L., Mouzakiti, A., Habens, F., Brimmell, 
M., Zhang, K. Y., Craig, R. W., Marcusson, E. G., Johnson, P. W., and Packham, 
G. (2004) Oncogene 23(28), 4818-4827 
185. Clohessy, J. G., Zhuang, J., and Brady, H. J. (2004) Br J Haematol 125(5), 655-
665 
186. Inoshita, S., Takeda, K., Hatai, T., Terada, Y., Sano, M., Hata, J., Umezawa, A., 
and Ichijo, H. (2002) J Biol Chem 277(46), 43730-43734 
187. Domina, A. M., Smith, J. H., and Craig, R. W. (2000) J Biol Chem 275(28), 
21688-21694 
188. Domina, A. M., Vrana, J. A., Gregory, M. A., Hann, S. R., and Craig, R. W. 
(2004) Oncogene 23(31), 5301-5315 
189. Zhong, Q., Gao, W., Du, F., and Wang, X. (2005) Cell 121(7), 1085-1095 
190. Kitada, S., Andersen, J., Akar, S., Zapata, J. M., Takayama, S., Krajewski, S., 
Wang, H. G., Zhang, X., Bullrich, F., Croce, C. M., Rai, K., Hines, J., and Reed, 
J. C. (1998) Blood 91(9), 3379-3389 
191. Ding, Q., He, X., Xia, W., Hsu, J. M., Chen, C. T., Li, L. Y., Lee, D. F., Yang, J. 
Y., Xie, X., Liu, J. C., and Hung, M. C. (2007) Cancer Res 67(10), 4564-4571 
192. Zhuang, L., Lee, C. S., Scolyer, R. A., McCarthy, S. W., Zhang, X. D., 
Thompson, J. F., and Hersey, P. (2007) Mod Pathol 20(4), 416-426 
104 
193. Maeta, Y., Tsujitani, S., Matsumoto, S., Yamaguchi, K., Tatebe, S., Kondo, A., 
Ikeguchi, M., and Kaibara, N. (2004) Gastric Cancer 7(2), 78-84 
194. Akgul, C., Turner, P. C., White, M. R., and Edwards, S. W. (2000) Cell Mol Life 
Sci 57(4), 684-691 
195. Freeman, S. N., Bepler, G., Haura, E., Sutphen, R., and Cress, W. D. (2005) J 
Natl Cancer Inst 97(14), 1088-1089; author reply 1093-1085 
196. Vargas, R. L., Felgar, R. E., and Rothberg, P. G. (2005) J Natl Cancer Inst 
97(14), 1089-1090; author reply 1093-1085 
197. Iglesias-Serret, D., Coll-Mulet, L., Santidrian, A. F., Navarro-Sabate, A., 
Domingo, A., Pons, G., and Gil, J. (2005) J Natl Cancer Inst 97(14), 1090-1091; 
author reply 1093-1095 
198. Dicker, F., Rauhut, S., Kohlmann, A., Kern, W., Schoch, C., Haferlach, T., and 
Schnittger, S. (2005) J Natl Cancer Inst 97(14), 1092-1093; author reply 1093-
1095 
199. Coenen, S., Pickering, B., Potter, K. N., Johnson, P. W., Stevenson, F. K., and 
Packham, G. (2005) Haematologica 90(9), 1285-1286 
200. Tobin, G., Skogsberg, A., Thunberg, U., Laurell, A., Aleskog, A., Merup, M., 
Sundstrom, C., Roos, G., Nilsson, K., and Rosenquist, R. (2005) Leukemia 19(5), 
871-873 
201. Nenning, U. C., Eckert, C., Wellmann, S., Barth, A., Henze, G., and Seeger, K. 
(2005) J Natl Cancer Inst 97(14), 1091-1092; author reply 1093-1095 
  
 
 
 
 
 
 
ABOUT THE AUTHOR 
Scott N. Freeman received his B.S. degree Cum Laude with a major in Biology 
and a minor in Chemistry from Central Michigan University in Mount Pleasant, 
Michigan in 2002. Scott N. Freeman continued his education by accepting a position in 
the Cancer Biology Ph.D. program at the University of South Florida where he conducted 
his graduate research under the supervision of W. Douglas Cress, Ph.D. at the H. Lee 
Moffitt Cancer Center and Research Institute. Scott N. Freeman has one first author 
publication in The Journal of the National Cancer Institute, a second author publication 
in Cancer Biology and Therapy, and at the time of this publication, has a first author 
publication pending for The Journal of Biological Chemistry.  
